Code,Country,Study,Tag,Created,Submission,Documents,Note
AT,Austria,Pre-Market,1.0,2022-03-14,Competent Authority,Application Form ,Download from webpage: https://applicationform.basg.gv.at/mpgform/faces/main. In PDF (signed electronically or scanned signed original) and XML 
AT,Austria,Pre-Market,1.0,2022-03-14,Competent Authority,CIP,With version number and date; compiled according to EN ISO 14155
AT,Austria,Pre-Market,1.0,2022-03-14,Competent Authority,IB,
AT,Austria,Pre-Market,1.0,2022-03-14,Competent Authority,IFU,German 
AT,Austria,Pre-Market,1.0,2022-03-14,Competent Authority,Favorable opinion of the EC,
AT,Austria,Pre-Market,1.0,2022-03-14,Competent Authority,Patient information and ICF,
AT,Austria,Pre-Market,1.0,2022-03-14,Competent Authority,Insurance coverage,
AT,Austria,Pre-Market,1.0,2022-03-14,Competent Authority,Written confirmation that the medical device complies with the essential requirements of the applicable Directive in all aspects except those that will be assessed in the CI,Directive 93/42/EEC Annex I &  Directive 90/385/EEC Annex 1
AT,Austria,Pre-Market,1.0,2022-03-14,Competent Authority,Declaration of conformity of the manufacturer,
AT,Austria,Pre-Market,1.0,2022-03-14,Competent Authority,CE marking certificate,
AT,Austria,Pre-Market,1.0,2022-03-14,Competent Authority,"PI CVs, GCPs",Dated and signed
AT,Austria,Pre-Market,1.0,2022-03-14,Competent Authority,"Written agreements between the sponsor, monitor, and clinical investigator establishing each party’s responsibilities",
AT,Austria,Pre-Market,1.0,2022-03-14,Competent Authority,CRF,
AT,Austria,Pre-Market,1.0,2022-03-14,Competent Authority,"Information on the construction and manufacture of the device, especially sterilisation",
AT,Austria,Pre-Market,1.0,2022-03-14,Competent Authority,"Results of construction calculations, assessments, technical tests, etc.",
AT,Austria,Pre-Market,1.0,2022-03-14,Competent Authority,Results of the risk analysis,"Risk analysis, risk minimisation measures See EN ISO 14971"
AT,Austria,Pre-Market,1.0,2022-03-14,Competent Authority,,
AT,Austria,Post-Market,1.0,2022-03-14,Competent Authority,Application Form ,Download from webpage: https://applicationform.basg.gv.at/mpgform/faces/main. In PDF (signed electronically or scanned signed original) and XML 
AT,Austria,Post-Market,1.0,2022-03-14,Competent Authority,CIP,With version number and date; compiled according to EN ISO 14155
AT,Austria,Post-Market,1.0,2022-03-14,Competent Authority,IB,
AT,Austria,Post-Market,1.0,2022-03-14,Competent Authority,IFU,German 
AT,Austria,Post-Market,1.0,2022-03-14,Competent Authority,Favorable opinion of the EC,
AT,Austria,Post-Market,1.0,2022-03-14,Competent Authority,Patient information and ICF,
AT,Austria,Post-Market,1.0,2022-03-14,Competent Authority,Insurance coverage,
AT,Austria,Post-Market,1.0,2022-03-14,Competent Authority,Written confirmation that the medical device complies with the essential requirements of the applicable Directive in all aspects except those that will be assessed in the CI,Directive 93/42/EEC Annex I &  Directive 90/385/EEC Annex 1
AT,Austria,Post-Market,1.0,2022-03-14,Competent Authority,Declaration of conformity of the manufacturer,
AT,Austria,Post-Market,1.0,2022-03-14,Competent Authority,CE marking certificate,
AT,Austria,Post-Market,1.0,2022-03-14,Competent Authority,"PI CVs, GCPs",Dated and signed
AT,Austria,Post-Market,1.0,2022-03-14,Competent Authority,"Written agreements between the sponsor, monitor, and clinical investigator establishing each party’s responsibilities",
AT,Austria,Post-Market,1.0,2022-03-14,Competent Authority,CRF,
AT,Austria,Post-Market,1.0,2022-03-14,Competent Authority,"Information on the construction and manufacture of the device, especially sterilisation",
AT,Austria,Post-Market,1.0,2022-03-14,Competent Authority,"Results of construction calculations, assessments, technical tests, etc.",
AT,Austria,Post-Market,1.0,2022-03-14,Competent Authority,Results of the risk analysis,"Risk analysis, risk minimisation measures See EN ISO 14971"
AT,Austria,Post-Market,1.0,2022-03-14,Competent Authority,,
BY,Belarus,Pre-Market,1.0,2022-03-14,Competent Authority,Register the device in the national system,Download form on webpgae. https://rceth.by/ru/Documents/Med/1 
BY,Belarus,Pre-Market,1.0,2022-03-14,Competent Authority,Guide for researcher= IB,
BY,Belarus,Pre-Market,1.0,2022-03-14,Competent Authority,Protocol & amendments ,Dated and signed
BY,Belarus,Pre-Market,1.0,2022-03-14,Competent Authority,ICF in local language,
BY,Belarus,Pre-Market,1.0,2022-03-14,Competent Authority,Subjects recruiment,
BY,Belarus,Pre-Market,1.0,2022-03-14,Competent Authority,Documents on the financial aspect,
BY,Belarus,Pre-Market,1.0,2022-03-14,Competent Authority,Proof of Insurance,
BY,Belarus,Pre-Market,1.0,2022-03-14,Competent Authority,Agreement between the parties,
BY,Belarus,Pre-Market,1.0,2022-03-14,Competent Authority,Permission to conduct a clinical trial,
BY,Belarus,Pre-Market,1.0,2022-03-14,Competent Authority,"PI & other staffs Cvs, GCPs",
BY,Belarus,Pre-Market,1.0,2022-03-14,Competent Authority,IFU ,
BY,Belarus,Pre-Market,1.0,2022-03-14,Competent Authority,Invoices (postal receipts) for the supply of the investigated medical device and medical equipment,
BY,Belarus,Pre-Market,1.0,2022-03-14,Competent Authority,Other documentations approve by the EC,
BY,Belarus,Post-Market,1.0,2022-03-14,Competent Authority,Register the device in the national system,Download form on webpgae. https://rceth.by/ru/Documents/Med/1 
BY,Belarus,Post-Market,1.0,2022-03-14,Competent Authority,Guide for researcher= IB,
BY,Belarus,Post-Market,1.0,2022-03-14,Competent Authority,Protocol & amendments ,Dated and signed
BY,Belarus,Post-Market,1.0,2022-03-14,Competent Authority,ICF in local language,
BY,Belarus,Post-Market,1.0,2022-03-14,Competent Authority,Subjects recruiment,
BY,Belarus,Post-Market,1.0,2022-03-14,Competent Authority,Documents on the financial aspect,
BY,Belarus,Post-Market,1.0,2022-03-14,Competent Authority,Proof of Insurance,
BY,Belarus,Post-Market,1.0,2022-03-14,Competent Authority,Agreement between the parties,
BY,Belarus,Post-Market,1.0,2022-03-14,Competent Authority,Permission to conduct a clinical trial,
BY,Belarus,Post-Market,1.0,2022-03-14,Competent Authority,"PI & other staffs Cvs, GCPs",
BY,Belarus,Post-Market,1.0,2022-03-14,Competent Authority,IFU ,
BY,Belarus,Post-Market,1.0,2022-03-14,Competent Authority,Invoices (postal receipts) for the supply of the investigated medical device and medical equipment,
BY,Belarus,Post-Market,1.0,2022-03-14,Competent Authority,Other documentations approve by the EC,
BE,Belgium,Pre-Market,1.0,2022-03-14,Competent Authority,COVER LETTER,It should be clearly mentioned which Belgian regulatory pathway is applicable: Consolidated opinion FAMHP and EC 
BE,Belgium,Pre-Market,1.0,2022-03-14,Competent Authority,List of documents submitted ,Template on website
BE,Belgium,Pre-Market,1.0,2022-03-14,Competent Authority,APPLICATION FORM,Template on website
BE,Belgium,Pre-Market,1.0,2022-03-14,Competent Authority,"CIP (with Annexes, version and date)",
BE,Belgium,Pre-Market,1.0,2022-03-14,Competent Authority,Synopsis,
BE,Belgium,Pre-Market,1.0,2022-03-14,Competent Authority,INVESTIGATOR’S BROCHURE (With annexes),
BE,Belgium,Pre-Market,1.0,2022-03-14,Competent Authority,Example of labels,
BE,Belgium,Pre-Market,1.0,2022-03-14,Competent Authority,LIST OF GENERAL SAFETY AND PERFORMANCE REQUIREMENTS,Template on website
BE,Belgium,Pre-Market,1.0,2022-03-14,Competent Authority,MANUFACTURER’S IFU,
BE,Belgium,Pre-Market,1.0,2022-03-14,Competent Authority,CLINICAL EVALUATION PLAN,
BE,Belgium,Pre-Market,1.0,2022-03-14,Competent Authority,PROOF OF INSURANCE,
BE,Belgium,Pre-Market,1.0,2022-03-14,Competent Authority,"PI Cvs, GCPs, & DOI ",
BE,Belgium,Pre-Market,1.0,2022-03-14,Competent Authority,SUITABILITY OF SITE(S),
BE,Belgium,Pre-Market,1.0,2022-03-14,Competent Authority,Agreements between parties,
BE,Belgium,Pre-Market,1.0,2022-03-14,Competent Authority,RECRUITMENT AND ADVERTISING,
BE,Belgium,Pre-Market,1.0,2022-03-14,Competent Authority,"PATIENT INFO, ICF AND ICF PROCEDURE",
BE,Belgium,Pre-Market,1.0,2022-03-14,Competent Authority,FINANCIAL AND OTHER ARRANGEMENTS,
BE,Belgium,Pre-Market,1.0,2022-03-14,Competent Authority,STATEMENT ON DATA PROTECTION,
BE,Belgium,Pre-Market,1.0,2022-03-14,Competent Authority,"If multinational, status on submission procedure(s) in other countries, including any approval or refusal letter if applicable.",
BE,Belgium,Pre-Market,1.0,2022-03-14,Competent Authority,CE certificate and manufacturer’s instructions for use of any comparator device used,
BE,Belgium,Post-Market,1.0,2022-03-14,Competent Authority,,
BE,Belgium,Post-Market,1.0,2022-03-14,Competent Authority,,
BE,Belgium,Post-Market,1.0,2022-03-14,Competent Authority,,
BE,Belgium,Post-Market,1.0,2022-03-14,Competent Authority,,
BE,Belgium,Post-Market,1.0,2022-03-14,Competent Authority,,
BE,Belgium,Post-Market,1.0,2022-03-14,Competent Authority,,
BE,Belgium,Post-Market,1.0,2022-03-14,Competent Authority,,
BE,Belgium,Post-Market,1.0,2022-03-14,Competent Authority,,
BE,Belgium,Post-Market,1.0,2022-03-14,Competent Authority,,
BE,Belgium,Post-Market,1.0,2022-03-14,Competent Authority,,
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Competent Authority,Cover Letter ,
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Competent Authority,Medical device identification data on paper & electronic carrier,
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Competent Authority,Clinical investigation plan (CIP),"Contain purpose, scientific, technical and medical reasons for conduction, scope, methodology and organization of investigation and number of devices"
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Competent Authority,"PI Cvs, GCPs",
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Competent Authority,Centres list,Name & address 
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Competent Authority,IB,
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Competent Authority,ICF & Patient information,
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Competent Authority,Declaration by the manufacturer whether the device to be tested can be defined as a device," according the Art. 3, pp. 2, 3 or 4 of MDL"
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Competent Authority,Start and end date and schedule of investigation,
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Competent Authority,Positive statement of Ethics Committee,submission to EC before
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Competent Authority,"Declaration, that medical device is in conformity with essential requirement",
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Competent Authority,Proof of insurance,
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Competent Authority,Contracts between parties,
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Competent Authority,Receipt of payment,Medical device law
BG,Bulgaria,Post-Market,1.0,2022-03-14,Competent Authority,Cover Letter ,
BG,Bulgaria,Post-Market,1.0,2022-03-14,Competent Authority,Medical device identification data on paper & electronic carrier,
BG,Bulgaria,Post-Market,1.0,2022-03-14,Competent Authority,Clinical investigation plan (CIP),"Contain purpose, scientific, technical and medical reasons for conduction, scope, methodology and organization of investigation and number of devices"
BG,Bulgaria,Post-Market,1.0,2022-03-14,Competent Authority,"PI Cvs, GCPs",
BG,Bulgaria,Post-Market,1.0,2022-03-14,Competent Authority,Centres list,Name & address 
BG,Bulgaria,Post-Market,1.0,2022-03-14,Competent Authority,IB,
BG,Bulgaria,Post-Market,1.0,2022-03-14,Competent Authority,ICF & Patient information,
BG,Bulgaria,Post-Market,1.0,2022-03-14,Competent Authority,Declaration by the manufacturer whether the device to be tested can be defined as a device," according the Art. 3, pp. 2, 3 or 4 of MDL"
BG,Bulgaria,Post-Market,1.0,2022-03-14,Competent Authority,Start and end date and schedule of investigation,
BG,Bulgaria,Post-Market,1.0,2022-03-14,Competent Authority,Positive statement of Ethics Committee,submission to EC before
BG,Bulgaria,Post-Market,1.0,2022-03-14,Competent Authority,"Declaration, that medical device is in conformity with essential requirement",
BG,Bulgaria,Post-Market,1.0,2022-03-14,Competent Authority,Proof of insurance,
BG,Bulgaria,Post-Market,1.0,2022-03-14,Competent Authority,Contracts between parties,
BG,Bulgaria,Post-Market,1.0,2022-03-14,Competent Authority,Receipt of payment,Medical device law
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,Authorisation aplication form,Download online 
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,Cover Letter,
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,interim EC opinion,
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,Foreign Competent Authority decision,If aplicable
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,CIP,
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,CRF,
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,ICF & patient information sheet,
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,Compliance with ISO 14155,
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,Up to date IB,
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,"IFU, if not integrated in IB",
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,Matrix of general safety and performance requirements and list of applicable standards,
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,"Confirmation that the documentation is being kept available in accordance with chapter III of Annex XV of the MDR for at least 10 years, 15 years in case of implants",
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,Proof of insurance,
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,Animal origin information ,If aplicable
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,MRI checklist,If aplicable
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,Ionising radiation information,If aplicable
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,Contract between Sponsor & manufacturer (if not the same one),
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,Trial center lists,Both in Switzerland and abroad
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,"PI CVs, GCPs; ",
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,,
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,,
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,,
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,,
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,,
CH,Switzerland,Pre-Market,1.0,2022-03-14,Competent Authority,"NOTE: the maximum file size should not exceed 200MB per PDF file. Larger files must be split. Documents formats: PDF, Excel & scanned documents. ",
CH,Switzerland,Post-Market,1.0,2022-03-14,Competent Authority,"NO NEED TO SUBMIT TO CA, EC ONLY. Category A clinical trials",
CH,Switzerland,Post-Market,1.0,2022-03-14,Competent Authority,,
CH,Switzerland,Post-Market,1.0,2022-03-14,Competent Authority,,
CH,Switzerland,Post-Market,1.0,2022-03-14,Competent Authority,,
CH,Switzerland,Post-Market,1.0,2022-03-14,Competent Authority,,
CH,Switzerland,Post-Market,1.0,2022-03-14,Competent Authority,,
CH,Switzerland,Post-Market,1.0,2022-03-14,Competent Authority,,
CH,Switzerland,Post-Market,1.0,2022-03-14,Competent Authority,,
CH,Switzerland,Post-Market,1.0,2022-03-14,Competent Authority,,
CH,Switzerland,Post-Market,1.0,2022-03-14,Competent Authority,,
CH,Switzerland,Post-Market,1.0,2022-03-14,Competent Authority,,
CH,Switzerland,Post-Market,1.0,2022-03-14,Competent Authority,,
CH,Switzerland,Post-Market,1.0,2022-03-14,Competent Authority,,
CH,Switzerland,Post-Market,1.0,2022-03-14,Competent Authority,,
CH,Switzerland,Post-Market,1.0,2022-03-14,Competent Authority,,
CH,Switzerland,Post-Market,1.0,2022-03-14,Competent Authority,,
CH,Switzerland,Post-Market,1.0,2022-03-14,Competent Authority,,
CH,Switzerland,Post-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Competent Authority,,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Competent Authority,,
CP,Unknown,Pre-Market,1.0,2022-03-14,Competent Authority,Aplication form ,Download from webpage
CP,Unknown,Pre-Market,1.0,2022-03-14,Competent Authority,A copy of the opinion of the Cyprus National Ethics Committee,
CP,Unknown,Pre-Market,1.0,2022-03-14,Competent Authority,Data allowing identification of the device,"(i) Generic Name (ii) Model name (iii) Model Number (i.e. Label, Instruction for Use)."
CP,Unknown,Pre-Market,1.0,2022-03-14,Competent Authority,A general description of the product  ,
CP,Unknown,Pre-Market,1.0,2022-03-14,Competent Authority,CIP,
CP,Unknown,Pre-Market,1.0,2022-03-14,Competent Authority,Criteria of patient selection,
CP,Unknown,Pre-Market,1.0,2022-03-14,Competent Authority,Number of patient in clinical investigation,
CP,Unknown,Pre-Market,1.0,2022-03-14,Competent Authority,"Design drawings and methods of manufacture envisaged, in particular as regards sterilization and diagrams of components, sub assemblies, circuits etc.",May not be submitted but must be available in case the CA wants.
CP,Unknown,Pre-Market,1.0,2022-03-14,Competent Authority,The results of the risk analysis & GSPRs analysis,
CP,Unknown,Pre-Market,1.0,2022-03-14,Competent Authority,The results of the design calculation and of the inspections and technical tests carried out ,
CP,Unknown,Pre-Market,1.0,2022-03-14,Competent Authority,"Summary of the experience with any similar device manufactured, including length of time on the market and a review of performance related complaints ",
CP,Unknown,Pre-Market,1.0,2022-03-14,Competent Authority,"Details of new or previously untested features of the device including where applicable, functions and principles of operation",
CP,Unknown,Pre-Market,1.0,2022-03-14,Competent Authority,Image of the device ,
CP,Unknown,Post-Market,1.0,2022-03-14,Competent Authority,Aplication form ,Download from webpage
CP,Unknown,Post-Market,1.0,2022-03-14,Competent Authority,A copy of the opinion of the Cyprus National Ethics Committee,
CP,Unknown,Post-Market,1.0,2022-03-14,Competent Authority,Data allowing identification of the device,"(i) Generic Name (ii) Model name (iii) Model Number (i.e. Label, Instruction for Use)."
CP,Unknown,Post-Market,1.0,2022-03-14,Competent Authority,A general description of the product  ,
CP,Unknown,Post-Market,1.0,2022-03-14,Competent Authority,CIP,
CP,Unknown,Post-Market,1.0,2022-03-14,Competent Authority,Criteria of patient selection,
CP,Unknown,Post-Market,1.0,2022-03-14,Competent Authority,Number of patient in clinical investigation,
CP,Unknown,Post-Market,1.0,2022-03-14,Competent Authority,"Design drawings and methods of manufacture envisaged, in particular as regards sterilization and diagrams of components, sub assemblies, circuits etc.",May not be submitted but must be available in case the CA wants.
CP,Unknown,Post-Market,1.0,2022-03-14,Competent Authority,The results of the risk analysis & GSPRs analysis,
CP,Unknown,Post-Market,1.0,2022-03-14,Competent Authority,The results of the design calculation and of the inspections and technical tests carried out ,
CP,Unknown,Post-Market,1.0,2022-03-14,Competent Authority,"Summary of the experience with any similar device manufactured, including length of time on the market and a review of performance related complaints ",
CP,Unknown,Post-Market,1.0,2022-03-14,Competent Authority,"Details of new or previously untested features of the device including where applicable, functions and principles of operation",
CP,Unknown,Post-Market,1.0,2022-03-14,Competent Authority,Image of the device ,
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Competent Authority,Investigator's Brochure IB,
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Competent Authority,CIP,
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Competent Authority,Approval of the EC,
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Competent Authority,ICF ,
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Competent Authority,Insurance information,
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Competent Authority,A declaration to the effect whether the medical device contains an active substance or a human blood or plasma derivative as its integral part (if aplicable),
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Competent Authority,A declaration to the effect whether the medical device has been manufactured using tissues of animal origin with a view to the minimisation of risk of transfer of TSE infection to man,
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Competent Authority,A declaration to the effect that the concerned medical device meets the basic requirements governing medical devices in conformity assessment,
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Competent Authority,Label of investigational medical device (in English or in Czech),
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Competent Authority,Extra information,The sponsors established outside the territory of the Czech Republic are highly recommended to consider cooperation with CROs established in the Czech Republic. Such cooperation might contribute to speeding up the processing of applications
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Competent Authority,,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Competent Authority,,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Competent Authority,,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Competent Authority,,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Competent Authority,,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Competent Authority,,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Competent Authority,,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Competent Authority,,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Competent Authority,,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Competent Authority,,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Competent Authority,,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Competent Authority,,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Competent Authority,,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Competent Authority,,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Competent Authority,,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Competent Authority,,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Competent Authority,,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Competent Authority,,
DK,Denmark,Pre-Market,1.0,2022-03-14,Competent Authority,SAME TO BOTH EC & CA,
DK,Denmark,Pre-Market,1.0,2022-03-14,Competent Authority,“01.01 Cover letter”,
DK,Denmark,Pre-Market,1.0,2022-03-14,Competent Authority,“01.02 Application form”,
DK,Denmark,Pre-Market,1.0,2022-03-14,Competent Authority,“02.01 Investigator Brocure”,
DK,Denmark,Pre-Market,1.0,2022-03-14,Competent Authority,“02.02 Instruction for use”,
DK,Denmark,Pre-Market,1.0,2022-03-14,Competent Authority,“02.03 Checklist for fulfilment of general safety performance requirements”,
DK,Denmark,Pre-Market,1.0,2022-03-14,Competent Authority,“03.01 Clinical investigation plan”,
DK,Denmark,Pre-Market,1.0,2022-03-14,Competent Authority,Patient information(s) and informed consent form(s),“04.01 Subject information and consent form patients”                                                                           “04.02 Subject information and consent form legal representative”; 04.03 and so on 
DK,Denmark,Pre-Market,1.0,2022-03-14,Competent Authority,Statement certifying that the device in question complies with the General safety and performance requirements,“05.01 Statement of compliance”
DK,Denmark,Pre-Market,1.0,2022-03-14,Competent Authority,CE certificate ,“05.02 Declaration of conformity”
DK,Denmark,Pre-Market,1.0,2022-03-14,Competent Authority,GDPR Data protection ,“06.01 sponsors statement on how to comply with GDPR”; 06.02… 
DK,Denmark,Pre-Market,1.0,2022-03-14,Competent Authority,Extra information (See note),Send documents to both EC & CA. 
DK,Denmark,Pre-Market,1.0,2022-03-14,Competent Authority,REQUIRED FROM EC,SEE EC EXCEL 
DK,Denmark,Post-Market,1.0,2022-03-14,Competent Authority,SAME TO BOTH EC & CA,ONLY SEND IF THE MD IS INVASIVE OR BURDENSOME
DK,Denmark,Post-Market,1.0,2022-03-14,Competent Authority,“01.01 Cover letter”,
DK,Denmark,Post-Market,1.0,2022-03-14,Competent Authority,“01.02 Application form”,
DK,Denmark,Post-Market,1.0,2022-03-14,Competent Authority,“02.01 Investigator Brocure”,
DK,Denmark,Post-Market,1.0,2022-03-14,Competent Authority,“02.02 Instruction for use”,
DK,Denmark,Post-Market,1.0,2022-03-14,Competent Authority,“02.03 Checklist for fulfilment of general safety performance requirements”,
DK,Denmark,Post-Market,1.0,2022-03-14,Competent Authority,“03.01 Clinical investigation plan”,
DK,Denmark,Post-Market,1.0,2022-03-14,Competent Authority,Patient information(s) and informed consent form(s),“04.01 Subject information and consent form patients”                                                                           “04.02 Subject information and consent form legal representative”; 04.03 and so on 
DK,Denmark,Post-Market,1.0,2022-03-14,Competent Authority,Statement certifying that the device in question complies with the General safety and performance requirements,“05.01 Statement of compliance”
DK,Denmark,Post-Market,1.0,2022-03-14,Competent Authority,CE certificate ,“05.02 Declaration of conformity”
DK,Denmark,Post-Market,1.0,2022-03-14,Competent Authority,GDPR Data protection ,“06.01 sponsors statement on how to comply with GDPR”; 06.02… 
DK,Denmark,Post-Market,1.0,2022-03-14,Competent Authority,Extra information (See note),Send documents to both EC & CA. 
DK,Denmark,Post-Market,1.0,2022-03-14,Competent Authority,REQUIRED FROM EC,SEE EC EXCEL 
DE,Germany,Pre-Market,1.0,2022-03-14,Competent Authority,Cover Letter,
DE,Germany,Pre-Market,1.0,2022-03-14,Competent Authority,Aplication Form,
DE,Germany,Pre-Market,1.0,2022-03-14,Competent Authority,IB,
DE,Germany,Pre-Market,1.0,2022-03-14,Competent Authority,CIP ,"Version, dated and signed"
DE,Germany,Pre-Market,1.0,2022-03-14,Competent Authority,Statement from sponsor of fulfilling the GSPRs,
DE,Germany,Pre-Market,1.0,2022-03-14,Competent Authority,Opinion of the EC,
DE,Germany,Pre-Market,1.0,2022-03-14,Competent Authority,Proof of insurance,
DE,Germany,Pre-Market,1.0,2022-03-14,Competent Authority,ICF,
DE,Germany,Pre-Market,1.0,2022-03-14,Competent Authority,Data protection,
DE,Germany,Pre-Market,1.0,2022-03-14,Competent Authority,Technical documentatiins of the device,
DE,Germany,Post-Market,1.0,2022-03-14,Competent Authority,"Note: If the clinical investigation is with a CE-marked medical device, within its intended purpose, is not exposed to any additional invasive or burdensome procedure → EC ONLY.",
DE,Germany,Post-Market,1.0,2022-03-14,Competent Authority,"Other cases: undergoing additional invasive or burdensome procedures, or use outside intended purpose → Full submission same as pre- market ",
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,MANDATORY,
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,Cover Letter,
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,Aplication Form ,Download from web
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,IB,Including annexes 
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,CIP,
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,CEP,
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,Synopsis,
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,Statement of conformity,
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,Example of labels,
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,Description of the arrangements to comply with the applicable rules on the protection and confidentiality of personal data/ personal information,
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,List of GSPRs ,
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,AS APLICABLE,
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,Description of the arrangements to comply with the applicable rules on the protection and confidentiality of personal data/ personal information,
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,Risk management,
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,Test reports,
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,Proof of clinical Insurance,
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,Suitability of investigational sites and investigation site team,
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,Manufacturer's IFU,
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,"PI CVs, GCPs",
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,Recruitment procedures,
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,ICF & related documentation,
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,Decisions from other countries,
EE,Estonia,Pre-Market,1.0,2022-03-14,Competent Authority,Receipt of state fee,"Beneficiary's name: Ministry of Finance
Account:
SEB Pank EE891010220034796011 (BIC / SWIFT: EEUHEE2X)
Swedbank EE932200221023778606 (BIC / SWIFT: HABAEE2X)
LHV Bank EE777700771003813400 (BIC / SWIFT: LHVBEE22)
Luminor Bank EE701700017001577198 (BIC / SWIFT: NDEAEE2X)

Reference number: 2900083031

 NB! The reference number is mandatory on bank transfer!"
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,MANDATORY,
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,Cover Letter,
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,Aplication Form ,Download from web
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,IB,Including annexes 
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,CIP,
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,CEP,
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,Synopsis,
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,Statement of conformity,
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,Example of labels,
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,Description of the arrangements to comply with the applicable rules on the protection and confidentiality of personal data/ personal information,
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,List of GSPRs ,
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,AS APLICABLE,
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,Description of the arrangements to comply with the applicable rules on the protection and confidentiality of personal data/ personal information,
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,Risk management,
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,Test reports,
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,Proof of clinical Insurance,
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,Suitability of investigational sites and investigation site team,
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,Manufacturer's IFU,
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,"PI CVs, GCPs",
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,Recruitment procedures,
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,ICF & related documentation,
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,CE certificate,
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,Decisions from other countries,
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,PMCF Plan,
EE,Estonia,Post-Market,1.0,2022-03-14,Competent Authority,Receipt of state fee,"Beneficiary's name: Ministry of Finance
Account:
SEB Pank EE891010220034796011 (BIC / SWIFT: EEUHEE2X)
Swedbank EE932200221023778606 (BIC / SWIFT: HABAEE2X)
LHV Bank EE777700771003813400 (BIC / SWIFT: LHVBEE22)
Luminor Bank EE701700017001577198 (BIC / SWIFT: NDEAEE2X)

Reference number: 2900083031

 NB! The reference number is mandatory on bank transfer!"
ES,Spain,Pre-Market,1.0,2022-03-14,Competent Authority,Cover Letter ,
ES,Spain,Pre-Market,1.0,2022-03-14,Competent Authority,Aplication Form ,
ES,Spain,Pre-Market,1.0,2022-03-14,Competent Authority,sponsor’s and manufacturer’s name & contact form,
ES,Spain,Pre-Market,1.0,2022-03-14,Competent Authority,Specify that It is the first submission,
ES,Spain,Pre-Market,1.0,2022-03-14,Competent Authority,All countries participants (if multicenter/nationals study),
ES,Spain,Pre-Market,1.0,2022-03-14,Competent Authority,EUDAMED ID (CIV ID),
ES,Spain,Pre-Market,1.0,2022-03-14,Competent Authority,EC opinion (asap),
ES,Spain,Pre-Market,1.0,2022-03-14,Competent Authority,CE mark certification,
ES,Spain,Pre-Market,1.0,2022-03-14,Competent Authority,CIP,
ES,Spain,Pre-Market,1.0,2022-03-14,Competent Authority,IB,
ES,Spain,Pre-Market,1.0,2022-03-14,Competent Authority,Proof of Insurance ,
ES,Spain,Pre-Market,1.0,2022-03-14,Competent Authority,ICF & Patient information documents,
ES,Spain,Pre-Market,1.0,2022-03-14,Competent Authority,"a statement indicating whether or not the device incorporates, as an integral part, a substance or human blood derivative referred to in Section 10 of Annex 1 of Directive 90/385/EEC respectively section 7.4 of Annex I of Directive 93/42/EEC;",
ES,Spain,Pre-Market,1.0,2022-03-14,Competent Authority,"PI CVs, GCPs",
ES,Spain,Post-Market,1.0,2022-03-14,Competent Authority,EC favorable responds,
ES,Spain,Post-Market,1.0,2022-03-14,Competent Authority,CE certification,
ES,Spain,Post-Market,1.0,2022-03-14,Competent Authority,CIP in Spanish,
ES,Spain,Post-Market,1.0,2022-03-14,Competent Authority,IFU in Spanish,
FI,Finland,Pre-Market,1.0,2022-03-14,Competent Authority,MANDATORY,
FI,Finland,Pre-Market,1.0,2022-03-14,Competent Authority,Cover letter,
FI,Finland,Pre-Market,1.0,2022-03-14,Competent Authority,Application form,
FI,Finland,Pre-Market,1.0,2022-03-14,Competent Authority,Investigator’s Brochure (including any annexes) ,
FI,Finland,Pre-Market,1.0,2022-03-14,Competent Authority,CIP,
FI,Finland,Pre-Market,1.0,2022-03-14,Competent Authority,CEP,
FI,Finland,Pre-Market,1.0,2022-03-14,Competent Authority,Synopsis,
FI,Finland,Pre-Market,1.0,2022-03-14,Competent Authority,Statement of conformity,
FI,Finland,Pre-Market,1.0,2022-03-14,Competent Authority,Example of labels,
FI,Finland,Pre-Market,1.0,2022-03-14,Competent Authority,The protection and confidentiality of personal data/ personal information,
FI,Finland,Pre-Market,1.0,2022-03-14,Competent Authority,List of GSPRs,
FI,Finland,Pre-Market,1.0,2022-03-14,Competent Authority,AS APLICABLE,
FI,Finland,Pre-Market,1.0,2022-03-14,Competent Authority,Risk management documentation,
FI,Finland,Pre-Market,1.0,2022-03-14,Competent Authority,Test reports,
FI,Finland,Pre-Market,1.0,2022-03-14,Competent Authority,Proof of Clinical Investigation Insurance,
FI,Finland,Pre-Market,1.0,2022-03-14,Competent Authority,Suitability of investigational sites and investigation site team,
FI,Finland,Pre-Market,1.0,2022-03-14,Competent Authority,Manufacturer’s Instructions for Use,
FI,Finland,Pre-Market,1.0,2022-03-14,Competent Authority,Suitability of the investigators,
FI,Finland,Pre-Market,1.0,2022-03-14,Competent Authority,Recruitment procedures and advertising materials,
FI,Finland,Pre-Market,1.0,2022-03-14,Competent Authority,"ICF, participants information, compensation….",
FI,Finland,Pre-Market,1.0,2022-03-14,Competent Authority,Decisions from other countries,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,MANDATORY,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,Cover letter,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,Application form,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,Investigator’s Brochure (including any annexes) ,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,CIP,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,CEP,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,Synopsis,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,Statement of conformity,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,Example of labels,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,The protection and confidentiality of personal data/ personal information,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,List of GSPRs,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,AS APLICABLE,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,Risk management documentation,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,Test reports,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,Proof of Clinical Investigation Insurance,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,Suitability of investigational sites and investigation site team,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,Manufacturer’s Instructions for Use,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,Suitability of the investigators,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,Recruitment procedures and advertising materials,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,"ICF, participants information, compensation….",
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,CE Certificate,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,Decisions from other countries,
FI,Finland,Post-Market,1.0,2022-03-14,Competent Authority,PMCF Plan,
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Main,
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Application form (FAEC) ,Please refer to Annex 2 of AAP-part 2
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Clinical evaluation plan (CEP),summary of the clinical evaluation plan (precise Version number and Date)
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Investigator brochure (IB),(precise version number and date)
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Clinical investigation plan (PROTOCOLE),Containing all items of annex XV chap II.3 (precise Version number and Date)
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Protocol synopsis (RESUME),French
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Other information (Please refer to Annex XV chap II 4),
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,"Signed statement by the natural or legal person responsible for the manufacture of the investigational device in question that it conforms to the general safety and performance requirements apart from the aspects covered by the clinical investigation and that, with regards to those aspects, every precaution has been taken to protect the health and safety of the subject",
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Signed statement that the sponsor is aware that the competent authority may contact the ethics committee that is assessing or has assessed the application,
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Proof of insurance (ASSURANCE) cover or indemnification of subjects in case of injury,"The proof of insurance cover must comply with the articles L. 1121-10 and 
R.1121-4 to R1121-9 of the French public health code. It must cover at least 
the period between the first inclusion and the last visit of a French participant. 
It must mention the estimated end date of the study and the contact details 
of the EU legal representative. IN FRENCH"
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Documents to be used to obtain informed consent (NIFC),"Please refer to page 7 of AAP-part 2 for details regarding the modalities of 
submission. IN FRENCH"
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,"Patient Information form (including all written information to participants, and compensation of participants)",In French
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Informed consent sheet,In French
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Informed consent process,In French
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,"All the document used to recruit participants (letter to general practitioners, posters, explanatory booklets, websites, etc.) (RECRUTEMENT)",In french
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Description of the arrangements to comply with the applicable rules on the protection and confidentiality of personal data/ personal information (refer to annex XV chap II 4.5) (DONNEES),Please refer to page 7 of AAP part 2 for details
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Copy of the opinion of the Ethics Committee (CPP) if available (to be submitted as soon as available) (AVIS),if applicable
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Technical file (DOSSIER_TECHNIQUE),
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Instruction for use for the clinical investigation ,Version No & Date
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,"Risk management, risk analysis",
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,List of standards and common specifications applied (if not included in the IB),(precise Version number and Date)
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,List of technical and functional features and the related expected clinical outcomes of the studied medical device,
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Critical analysis of non-clinical and clinical data related to the MD studied in relation to the evaluation of the benefits and risks of the investigation,
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Pre-clinical data,
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Clinical data,
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Other documents - National requirements (DOCUMENTS),
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,"Investigator list, proof of suitability of clinical investigators (LISTE_CV) and of suitability of investigational sites and investigational site team (EQUIPEMENT) ",Please refer to page 7 of AAP for details regarding the CV
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Authorisation of the investigational site (JUS_EQUIPEMENT),
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Import certificate for investigational medicinal products used in the IC ,If applicable. In French
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,Copy of the authorization issued by the third party to the sponsor to communicate the data related to the MD,
FR,France,Pre-Market,1.0,2022-03-14,Competent Authority,PMCF plan,
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,Main,
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,Application form (FAEC) ,Please refer to Annex 2 of AAP-part 2
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,Clinical evaluation plan (CEP),summary of the clinical evaluation plan (precise Version number and Date)
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,Instruction for use (IFU) for CE medical device used within or without the scope of its intended purpose,(precise version number and date)
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,Clinical investigation plan (PROTOCOLE),Containing all items of annex XV chap II.3 (precise Version number and Date)
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,Protocol synopsis (RESUME),French
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,Other information (Please refer to Annex XV chap II 4),
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,Signed statement that the sponsor is aware that the competent authority may contact the ethics committee that is assessing or has assessed the application,
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,Proof of insurance (ASSURANCE) cover or indemnification of subjects in case of injury,"The proof of insurance cover must comply with the articles L. 1121-10 and 
R.1121-4 to R1121-9 of the French public health code. It must cover at least 
the period between the first inclusion and the last visit of a French participant. 
It must mention the estimated end date of the study and the contact details 
of the EU legal representative. IN FRENCH"
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,Documents to be used to obtain informed consent (NIFC),"Please refer to page 7 of AAP-part 2 for details regarding the modalities of 
submission. IN FRENCH"
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,"Patient Information form (including all written information to participants, and compensation of participants)",In French
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,Informed consent sheet,In French
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,Informed consent process,In French
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,"All the document used to recruit participants (letter to general practitioners, posters, explanatory booklets, websites, etc.) (RECRUTEMENT)",In french
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,Description of the arrangements to comply with the applicable rules on the protection and confidentiality of personal data/ personal information (refer to annex XV chap II 4.5) (DONNEES),Please refer to page 7 of AAP part 2 for details
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,Copy of the opinion of the Ethics Committee (CPP) if available (to be submitted as soon as available) (AVIS),if applicable
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,Technical file (DOSSIER_TECHNIQUE),
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,Statement of conformity: EC declaration of conformity or EU declaration of conformity ,(refer to art.19)
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,EC certificate,
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,Instructions for use for the clinical investigation ,(precise Version number and Date)
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,Other documents - National requirements (DOCUMENTS),
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,"Investigator list, proof of suitability of clinical investigators (LISTE_CV) and of suitability of investigational sites and investigational site team (EQUIPEMENT) ",Please refer to page 7 of AAP for details regarding the CV
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,Import certificate for investigational medicinal products used in the IC ,If applicable. In French
FR,France,Post-Market,1.0,2022-03-14,Competent Authority,PMCF plan,
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,I. Cover letter containing a list of contents and the total budget of the study in Greece (summary),
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,"II. General Part: The documentation to be included in the General Part of the filing file to the EOF is set out in Annex XV, Chapter II of Regulation (EU) 2017/745.",
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,Application Form,
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,Investigator Brochure (IB),
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,Clinical Investigation Plan (CIP),
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,Compliance statement letter,
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,Insurance certificate,
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,Patient informed consent form (ICF),
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,Data confidentiality letter,
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,Instruction for use (IFU),
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,Case report form (CRF),
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,"III. Special Part: In addition to the supporting documents of the General Part, the file to the EOF will include the following Special supporting documents:",
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,"Completed the application form in Greek (available on the EOF website), in searchable pdf format, with signature, signatory details and date  ",
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,"General Summary of the clinical investigation plan (SYNOPSIS) in the Greek language (Relative to Section 3.1.5 of Reg. 2017/745, Par. XV, Chapter II)",
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,"Patient information and consent form (s), in Greek (& original in English if available). ",
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,Agreement PI & Sponsor,
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,"PI CVs, GCPs",
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,"If the applicant is not the sponsor, a letter of authorization to the applicant to act on behalf of the sponsor.",
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,CE marking certificate (if aplicable),
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,"Model of the label in the Greek language in which there will be, among other information, the labeling ""exclusively for clinical trials"".",
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,"Responsible statement from the sponsor stating whether the product contains as an integral part of the substance or derivative of human blood (in addition to Point 2.6 of Reg. 2017/745, Par. XV, Chapter II).",
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,Proof of payment of a fee in favor of EOF,
GK,Guernse,Pre-Market,1.0,2022-03-14,Competent Authority,Study Budget,
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,I. Cover letter which will include a list of contents,
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,"II. General Part: The documentation to be included in the General Part of the filing file to the EOF is set out in Annex XV, Chapter II of Regulation (EU) 2017/745.",
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,Application Form,
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,Investigator Brochure (IB),
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,Clinical Investigation Plan (CIP),
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,Compliance statement letter,
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,Insurance certificate,
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,Patient informed consent form (ICF),
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,Data confidentiality letter,
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,Instruction for use (IFU),
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,Case report form (CRF),
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,"III. Special Part: In addition to the supporting documents of the General Part, the file to the EOF will include the following Special supporting documents:",
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,"Completed the application form in Greek (available on the EOF website), in searchable pdf format, with signature, signatory details and date  ",
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,"General Summary of the clinical investigation plan (SYNOPSIS) in the Greek language (Relative to Section 3.1.5 of Reg. 2017/745, Par. XV, Chapter II)",
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,"Patient information and consent form (s), in Greek (& original in English if available). ",
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,Agreement PI & Sponsor,
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,"PI CVs, GCPs",
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,"If the applicant is not the sponsor, a letter of authorization to the applicant to act on behalf of the sponsor.",
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,CE marking certificate (if aplicable),
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,"Model of the label in the Greek language in which there will be, among other information, the labeling ""exclusively for clinical trials"".",
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,"Responsible statement from the sponsor stating whether the product contains as an integral part of the substance or derivative of human blood (in addition to Point 2.6 of Reg. 2017/745, Par. XV, Chapter II).",
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,Proof of payment of a fee in favor of EOF,
GK,Guernse,Post-Market,1.0,2022-03-14,Competent Authority,Study Budget,
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Competent Authority,Cover Letter,Hungarian
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Competent Authority,Proof of payment,
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Competent Authority,Ethical favorable opinion from EC,Hungarian
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Competent Authority,APLICATION FORM ,See MDCG 2021-08 guide
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Competent Authority,"A description compiled for the examiner, the content of which complies with the provisions of MDR XV.",
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Competent Authority,CIP,
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Competent Authority,Monitoring plan if not included in CIP,
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Competent Authority,Synopsis,Hungarian
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Competent Authority,IFU,Hungarian
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Competent Authority,Documentation ofr comparator device,If aplicable
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Competent Authority,Technical documention. Device information,
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Competent Authority,Proof of insurance,
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Competent Authority,"Documents to be used to obtain the informed consent, including the package leaflet and the informed consent",Hungarian
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Competent Authority,Data protection,
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Competent Authority,Agreements between parties ,Hungarian
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Competent Authority,"PI CVs, GCPs",Hungarian
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Competent Authority,A statement from the head of the medical institution providing the test site stating that he is aware of the intention to conduct the test agrees with the personal and material conditions are provided for the investigation.,Hungarian
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Competent Authority,Cover Letter,Hungarian
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Competent Authority,Proof of payment,
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Competent Authority,Ethical favorable opinion from EC,Hungarian
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Competent Authority,APLICATION FORM ,See MDCG 2021-08 guide
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Competent Authority,"A description compiled for the examiner, the content of which complies with the provisions of MDR XV.",
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Competent Authority,CIP,
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Competent Authority,Monitoring plan if not included in CIP,
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Competent Authority,Synopsis,Hungarian
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Competent Authority,CE Certificate ,
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Competent Authority,IFU,Hungarian
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Competent Authority,Documentation ofr comparator device,If aplicable
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Competent Authority,Technical documention. Device information,
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Competent Authority,Proof of insurance,
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Competent Authority,"Documents to be used to obtain the informed consent, including the package leaflet and the informed consent",Hungarian
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Competent Authority,Data protection,
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Competent Authority,Agreements between parties ,Hungarian
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Competent Authority,"PI CVs, GCPs",Hungarian
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Competent Authority,A statement from the head of the medical institution providing the test site stating that he is aware of the intention to conduct the test agrees with the personal and material conditions are provided for the investigation.,Hungarian
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,Application form,Download from web
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,CIP,"Version and Date, and amendments"
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,Statement of compliance with the recognised ethical principles for medical research involving humans and the principles of good clinical practice in the field of clinical investigations of devices and with applicable regulatory requirements,
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,Sponsor's contact details,
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,"Identification of the principal investigator at each investigational site, the coordinating investigator, address details for each investigational site, emergency contact details for the principal investigator at each site. The roles, responsibilities and qualifications of the investigators must also be specified in the CIP.",
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,Funding & agreements,
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,Synopsis ,In EN
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,Identification and description of the device,
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,Risk assessments ,
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,Description of the relevance of the clinical investigation in the context of the state of the art of clinical practice,
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,Objectives and hypotheses of the clinical investigation,
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,"Full description and justification of investigation design with evidence of its scientific robustness and validity, including criteria used for decision making, e.g. meeting end point, stopping criteria",
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,ICF & patient information,
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,Policy regarding follow-up and management of any deviations from investigation protocol,
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,Device accountability,
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,"Proposed clinical and procedural follow-up protocols for participants, both during and after the clinical investigation, if applicable",
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,Data management plan,
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,Monitoring plan,
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,Safety reports,
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,IB ,
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,Pre-clinical & clinical information ,
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,EC ,
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,Copy of Opinion of the EC,
IE,Ireland,Pre-Market,1.0,2022-03-14,Competent Authority,Proof of insurance,
IE,Ireland,Post-Market,1.0,2022-03-14,Competent Authority,Aplication Form,Download from web
IE,Ireland,Post-Market,1.0,2022-03-14,Competent Authority,CIP,"Dated, Version No"
IE,Ireland,Post-Market,1.0,2022-03-14,Competent Authority,IB OR IFU,
IE,Ireland,Post-Market,1.0,2022-03-14,Competent Authority,Opinion from EC,
IE,Ireland,Post-Market,1.0,2022-03-14,Competent Authority,Documents used to obtain informed consent,
IE,Ireland,Post-Market,1.0,2022-03-14,Competent Authority,Statement on Data Protection,
IE,Ireland,Post-Market,1.0,2022-03-14,Competent Authority,CE marking,
IE,Ireland,Post-Market,1.0,2022-03-14,Competent Authority,"PI Cvs, GCPs",
IE,Ireland,Post-Market,1.0,2022-03-14,Competent Authority,,
IE,Ireland,Post-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Post-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Post-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Post-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Post-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Post-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Post-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Post-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Post-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Post-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Post-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Post-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Post-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Post-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Post-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Post-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Post-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Post-Market,1.0,2022-03-14,Competent Authority,,
IS,Iceland,Post-Market,1.0,2022-03-14,Competent Authority,,
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Letter of request, Italian or bilingual Italian/ English
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Application form (IT or EN version),"Italian or English, including Appendix showing the list of documents supporting the application."
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Investigator's dossier,"Manufacturer's Instructions, Label Examples, Instructions for Use, List of General Safety and Performance Requirements and Applicable Standards, Summary of Risk, Benefit and risk management"
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,CIP with Synopsis ,Same language CIP & Synopsis
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Declaration that devices complies with the GSPRs ,
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Copy of the opinion / single opinion issued by the Ethics Committee / Coordinating Ethics Committee ,depending on whether the trial centers in Italy are one or more than one
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Proof of insurance coverage or indemnification,
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,"ICF, including the patient information sheet ",Italian
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Protection and confidentiality of personal data,
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,"Proof of payment of the fee of € 2,245.20",
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Substitutive declaration of the deed of notoriety of the natural person acting as the legal representative of the Sponsor,Download from webpage 
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Substitutive declaration of the deed of notoriety of the natural person acting as legal representative of the manufacturing manager,Download from webpage
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Copy of any power of attorney to the person who submits the application and is the recipient of the communications from the Competent Authority,Download from webpage
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Documentation relating to the suitability of the health facility (s) of the investigator (s),
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,"List of trial centers and related ethics committees, including all their PEC addresses",
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,"Other documents, where applicable ","e.g. Opinion of the group of experts, Decisions of other Competent Authorities, PMCF Plan, Documentation of recruitment procedures and advertising material, any opinions of other Ethics Committees)"
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Investigator's application dated and signed,
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,"If the study is sponsored, receipt of the transfer or declaration from the Promoter in the case of a non-profit study",
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,,
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,,
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,,
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,,
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,,
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,,
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,,
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,,
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,EC documents list,
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,"Please submit the following application in this way: Send a hard copy and an electronic copy (cd-rom) of the documents listed below to the Secretariat Office of the Ethics Committee, Pav. 3 - New Entrance Careggi (NIC) - Didactics - Largo Brambilla, 3 - 50134 Florence",Region Toscana: https://www.aou-careggi.toscana.it/internet/index.php?option=com_content&view=article&id=4385&Itemid=962&lang=it
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Documents ,Note
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Letter of Intent (Form in webpage),
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Synopsis in Italian (Form in webpage),
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Complete study protocol and any amendments with version and date on each page (CIP),
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,List of participating sites,
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Data collection information (CRF),
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Insurance certificate in Italian (if applicable),
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Receipt of the payment of the amount established by the Tuscany Region for the examination of the study protocol,
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Economic agreement (Form on webpage),
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Informed Consent Form in Italian (Form on webpage),
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Device user manual = IFU?,
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,CE Marking Certification ,
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Device Preliminary CheckList (Form in webpage),CHECK if the device has registered in Italy. https://www.salute.gov.it/interrogazioneDispositivi/RicercaDispositiviServlet?action=ACTION_MASCHERA 
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,PI Acceptance Form (on webpage),
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,"PI CVs, GCPs.. Up to date",
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Feasibility Assessment (Form on webpage),
IT,Italy,Pre-Market,1.0,2022-03-14,Competent Authority,Public Statement on Local Investigator's Conflict of Interest (Form on webpage),
IT,Italy,Post-Market,1.0,2022-03-14,Competent Authority,Letter of request, Italian or bilingual Italian/ English
IT,Italy,Post-Market,1.0,2022-03-14,Competent Authority,Application form (download from web IT/EN version),"Italian or English, including Appendix showing the list of documents supporting the application."
IT,Italy,Post-Market,1.0,2022-03-14,Competent Authority,Investigator's dossier,"Manufacturer's Instructions, Label Examples, Instructions for Use, List of General Safety and Performance Requirements and Applicable Standards, Summary of Risk, Benefit and risk management"
IT,Italy,Post-Market,1.0,2022-03-14,Competent Authority,CIP with Synopsis ,Same language CIP & Synopsis
IT,Italy,Post-Market,1.0,2022-03-14,Competent Authority,Declaration that devices complies with the GSPRs ,
IT,Italy,Post-Market,1.0,2022-03-14,Competent Authority,Copy of the opinion / single opinion issued by the Ethics Committee / Coordinating Ethics Committee ,depending on whether the trial centers in Italy are one or more than one
IT,Italy,Post-Market,1.0,2022-03-14,Competent Authority,Proof of insurance coverage or indemnification,
IT,Italy,Post-Market,1.0,2022-03-14,Competent Authority,"ICF, including the patient information sheet ",Italian
IT,Italy,Post-Market,1.0,2022-03-14,Competent Authority,Protection and confidentiality of personal data,
IT,Italy,Post-Market,1.0,2022-03-14,Competent Authority,"Proof of payment of the fee of € 2,245.20",
IT,Italy,Post-Market,1.0,2022-03-14,Competent Authority,Substitutive declaration of the deed of notoriety of the natural person acting as the legal representative of the Sponsor,
IT,Italy,Post-Market,1.0,2022-03-14,Competent Authority,Substitutive declaration of the deed of notoriety of the natural person acting as legal representative of the manufacturing manager,
IT,Italy,Post-Market,1.0,2022-03-14,Competent Authority,Copy of any power of attorney to the person who submits the application and is the recipient of the communications from the Competent Authority,
IT,Italy,Post-Market,1.0,2022-03-14,Competent Authority,Documentation relating to the suitability of the health facility (s) of the investigator (s),
IT,Italy,Post-Market,1.0,2022-03-14,Competent Authority,"List of trial centers and related ethics committees, including all their PEC addresses",
IT,Italy,Post-Market,1.0,2022-03-14,Competent Authority,"Other documents, where applicable ","e.g. Opinion of the group of experts, Decisions of other Competent Authorities, PMCF Plan, Documentation of recruitment procedures and advertising material, any opinions of other Ethics Committees)"
LT,Lithuania,Pre-Market,1.0,2022-03-14,Competent Authority,Application Form,Download from web https://e-seimas.lrs.lt/portal/legalAct/lt/TAD/6abb8a40302911eb8c97e01ffe050e1c?jfwid=-vvhf0h3w
LT,Lithuania,Pre-Market,1.0,2022-03-14,Competent Authority,CEP,Dated version and signed
LT,Lithuania,Pre-Market,1.0,2022-03-14,Competent Authority,"Information on whether the medical device contains a medicinal substance, including a human blood or plasma derivative, or is manufactured using non-viable tissues or cells or derivatives thereof of human or animal origin",
LT,Lithuania,Pre-Market,1.0,2022-03-14,Competent Authority,Summary of the clinical trial design,"the purpose (s) of the clinical trial, the number and sex of subjects, the selection criteria, the design of the study in subjects under 18 years of age, such as controlled and / or randomized trials study, scheduled start and end dates of the clinical trial"
LT,Lithuania,Pre-Market,1.0,2022-03-14,Competent Authority,"Infromation of the comparartor, if applicable",
LT,Lithuania,Pre-Market,1.0,2022-03-14,Competent Authority,Site sustainability ,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Competent Authority,"PI CVs, GCPs",
LT,Lithuania,Pre-Market,1.0,2022-03-14,Competent Authority,Statement of the sporsor about compliance with GSPRs,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Competent Authority,IB,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Competent Authority,CIP,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Competent Authority,Proof of insurance,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Competent Authority,Patient information & ICF,
LT,Lithuania,Post-Market,1.0,2022-03-14,Competent Authority,Application Form,Download from web https://e-seimas.lrs.lt/portal/legalAct/lt/TAD/6abb8a40302911eb8c97e01ffe050e1c?jfwid=-vvhf0h3w
LT,Lithuania,Post-Market,1.0,2022-03-14,Competent Authority,CEP,Dated version and signed
LT,Lithuania,Post-Market,1.0,2022-03-14,Competent Authority,"Information on whether the medical device contains a medicinal substance, including a human blood or plasma derivative, or is manufactured using non-viable tissues or cells or derivatives thereof of human or animal origin",
LT,Lithuania,Post-Market,1.0,2022-03-14,Competent Authority,Summary of the clinical trial design,"the purpose (s) of the clinical trial, the number and sex of subjects, the selection criteria, the design of the study in subjects under 18 years of age, such as controlled and / or randomized trials study, scheduled start and end dates of the clinical trial"
LT,Lithuania,Post-Market,1.0,2022-03-14,Competent Authority,"Infromation of the comparartor, if applicable",
LT,Lithuania,Post-Market,1.0,2022-03-14,Competent Authority,Site sustainability ,
LT,Lithuania,Post-Market,1.0,2022-03-14,Competent Authority,"PI CVs, GCPs",
LT,Lithuania,Post-Market,1.0,2022-03-14,Competent Authority,Statement of the sporsor about compliance with GSPRs,
LT,Lithuania,Post-Market,1.0,2022-03-14,Competent Authority,IB,
LT,Lithuania,Post-Market,1.0,2022-03-14,Competent Authority,CIP,
LT,Lithuania,Post-Market,1.0,2022-03-14,Competent Authority,Proof of insurance,
LT,Lithuania,Post-Market,1.0,2022-03-14,Competent Authority,Patient information & ICF,
LV,Latvia,Pre-Market,1.0,2022-03-14,Competent Authority,Cover Letter,
LV,Latvia,Pre-Market,1.0,2022-03-14,Competent Authority,Aplication form ,Download from the web
LV,Latvia,Pre-Market,1.0,2022-03-14,Competent Authority,Protocols,
LV,Latvia,Pre-Market,1.0,2022-03-14,Competent Authority,Proof of insurnace,
LV,Latvia,Pre-Market,1.0,2022-03-14,Competent Authority,CE marking certification,
LV,Latvia,Pre-Market,1.0,2022-03-14,Competent Authority,Description of the initiated surveillance and control method of clinical trial,
LV,Latvia,Pre-Market,1.0,2022-03-14,Competent Authority,"PI CVs, GCPs",
LV,Latvia,Pre-Market,1.0,2022-03-14,Competent Authority,An example of a register form for data obtained through clinical trial ,version number and date
LV,Latvia,Pre-Market,1.0,2022-03-14,Competent Authority,Written statement of PI that the clinical trial will be performed according to the trial plan and in compliance with requirements set out in the regilatory enactments ,
LV,Latvia,Pre-Market,1.0,2022-03-14,Competent Authority,Patient information and ICF,
LV,Latvia,Pre-Market,1.0,2022-03-14,Competent Authority,Description of identification measures for the research involving person,
LV,Latvia,Pre-Market,1.0,2022-03-14,Competent Authority,Recruitment plan,
LV,Latvia,Pre-Market,1.0,2022-03-14,Competent Authority,"Operational parameters of a medical device, malfunctions of the device and control of the measures related to elimination of malfunctions",
LV,Latvia,Pre-Market,1.0,2022-03-14,Competent Authority,EC favorable opinion. If aplicable,
LV,Latvia,Post-Market,1.0,2022-03-14,Competent Authority,Cover Letter,
LV,Latvia,Post-Market,1.0,2022-03-14,Competent Authority,Aplication form ,Download from the web
LV,Latvia,Post-Market,1.0,2022-03-14,Competent Authority,Protocols,
LV,Latvia,Post-Market,1.0,2022-03-14,Competent Authority,Proof of insurnace,
LV,Latvia,Post-Market,1.0,2022-03-14,Competent Authority,CE marking certification,
LV,Latvia,Post-Market,1.0,2022-03-14,Competent Authority,Description of the initiated surveillance and control method of clinical trial,
LV,Latvia,Post-Market,1.0,2022-03-14,Competent Authority,"PI CVs, GCPs",
LV,Latvia,Post-Market,1.0,2022-03-14,Competent Authority,An example of a register form for data obtained through clinical trial ,version number and date
LV,Latvia,Post-Market,1.0,2022-03-14,Competent Authority,Written statement of PI that the clinical trial will be performed according to the trial plan and in compliance with requirements set out in the regilatory enactments ,
LV,Latvia,Post-Market,1.0,2022-03-14,Competent Authority,Patient information and ICF,
LV,Latvia,Post-Market,1.0,2022-03-14,Competent Authority,Description of identification measures for the research involving person,
LV,Latvia,Post-Market,1.0,2022-03-14,Competent Authority,Recruitment plan,
LV,Latvia,Post-Market,1.0,2022-03-14,Competent Authority,"Operational parameters of a medical device, malfunctions of the device and control of the measures related to elimination of malfunctions",
LV,Latvia,Post-Market,1.0,2022-03-14,Competent Authority,EC favorable opinion. If aplicable,
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Competent Authority,Cover Letter ( Requesting authorisation for the study),File name: Protocol number_courrierAEC_date(ddmmyy)_version
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Competent Authority,Aplication form ,
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Competent Authority,EU test number & Universal test number ,
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Competent Authority,Protocol ,File name: Protocol number_protocol_date(ddmmyy)_version
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Competent Authority,Protocol summary/ Synopsis,File name: Protocol number_summary_date(ddmmyy)_version
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Competent Authority,IB,File name: Protocol number_BI_date(ddmmyy)_version
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Competent Authority,Dossier of the investigational product,
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Competent Authority,"CE Certificate, if aplicable",
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Competent Authority,Manufacturing and import authorization,
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Competent Authority,Labeling of investigational product,
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Competent Authority,"Scientific advice and pediatric investigation plan (PIP), if applicable",
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Competent Authority,Technical File,File name: Protocol number_DT_date(ddmmyy)_version
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Competent Authority,"CRF, evaluation grids, questionnaire",
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Competent Authority,"PI Cvs, GCPs",
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Competent Authority,ICF & patient information,French & German 
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Competent Authority,Proof of insurance or compensation,
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Competent Authority,Justification of the adequacy of the infrastructures,
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Competent Authority,Study funding,
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Competent Authority,Proof of payment fee,
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Competent Authority,NOTE,The Luxembourg Ministry of Health is the only point of submission of files. The Ministry of Health is responsible for sending the study files to the Health Department and the National Research Ethics Committee.
LU,Luxembourg,Post-Market,1.0,2022-03-14,Competent Authority,Cover Letter ( Requesting authorisation for the study),File name: Protocol number_courrierAEC_date(ddmmyy)_version
LU,Luxembourg,Post-Market,1.0,2022-03-14,Competent Authority,Aplication form ,
LU,Luxembourg,Post-Market,1.0,2022-03-14,Competent Authority,EU test number & Universal test number ,
LU,Luxembourg,Post-Market,1.0,2022-03-14,Competent Authority,Protocol ,File name: Protocol number_protocol_date(ddmmyy)_version
LU,Luxembourg,Post-Market,1.0,2022-03-14,Competent Authority,Protocol summary/ Synopsis,File name: Protocol number_summary_date(ddmmyy)_version
LU,Luxembourg,Post-Market,1.0,2022-03-14,Competent Authority,IB,File name: Protocol number_BI_date(ddmmyy)_version
LU,Luxembourg,Post-Market,1.0,2022-03-14,Competent Authority,Dossier of the investigational product,
LU,Luxembourg,Post-Market,1.0,2022-03-14,Competent Authority,"CE Certificate, if aplicable",
LU,Luxembourg,Post-Market,1.0,2022-03-14,Competent Authority,Manufacturing and import authorization,
LU,Luxembourg,Post-Market,1.0,2022-03-14,Competent Authority,Labeling of investigational product,
LU,Luxembourg,Post-Market,1.0,2022-03-14,Competent Authority,"Scientific advice and pediatric investigation plan (PIP), if applicable",
LU,Luxembourg,Post-Market,1.0,2022-03-14,Competent Authority,Technical File,File name: Protocol number_DT_date(ddmmyy)_version
LU,Luxembourg,Post-Market,1.0,2022-03-14,Competent Authority,"CRF, evaluation grids, questionnaire",
LU,Luxembourg,Post-Market,1.0,2022-03-14,Competent Authority,"PI Cvs, GCPs",
LU,Luxembourg,Post-Market,1.0,2022-03-14,Competent Authority,ICF & patient information,French & German 
LU,Luxembourg,Post-Market,1.0,2022-03-14,Competent Authority,Proof of insurance or compensation,
LU,Luxembourg,Post-Market,1.0,2022-03-14,Competent Authority,Justification of the adequacy of the infrastructures,
LU,Luxembourg,Post-Market,1.0,2022-03-14,Competent Authority,Study funding,
LU,Luxembourg,Post-Market,1.0,2022-03-14,Competent Authority,Proof of payment fee,
LU,Luxembourg,Post-Market,1.0,2022-03-14,Competent Authority,NOTE,The Luxembourg Ministry of Health is the only point of submission of files. The Ministry of Health is responsible for sending the study files to the Health Department and the National Research Ethics Committee.
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Competent Authority,Aplication Form (Annex I),2 copies of Annex I available from page http://lex.justice.md/index.php?action=view&view=doc&lang=1&id=375209
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Competent Authority,Annex II,2 copies of Annex II available from page http://lex.justice.md/index.php?action=view&view=doc&lang=1&id=375209
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Competent Authority,the manufacturer's registration certificate or other officially registered document,
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Competent Authority,Authenticated declaration of conformity with the signature of the manufacturer and the authorized representative.,
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Competent Authority,medical device label (including state language).,
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Competent Authority,IFU,
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Competent Authority,the document by which the manufacturer give the authorization to the representative in Moldova. ,authenticated by the signature of the manufacturer and the authorized representative.
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Competent Authority,Notification form ,"Annex I. 2 copies, download from "
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Competent Authority,the EC declaration of conformity issued by the manufacturer for the manufactured medical device;,
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Competent Authority,"the CE certificate of conformity valid for the manufactured devices, as the case may be;",
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Competent Authority,the act by which the manufacturer appoints his representative.,Signatures of both in the documents
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Competent Authority,the declaration on his own responsibility regarding the veracity of the data presented .,Annex II
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Competent Authority,Note: , the file is submitted on paper at the entrance to the Agency in the mailbox. Check if the devices is registed in the state web: http://89.32.230.138:8081/dispozitive/ 
NL,Netherlands,Pre-Market,1.0,2022-03-14,Competent Authority,NOTE,See requirement for EC. Same
NL,Netherlands,Post-Market,1.0,2022-03-14,Competent Authority,NOTE,See requirement for EC. Same
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,COMPULSORY DOCUMENTS,From 1 to 15
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,Documentation requirements and overview of submitted documents (this document),Download from website
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,Cover Letter,Please use the template provided by NoMA
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,Aplication form,Please use the template provided by NoMA
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,Appendix I,Please use the template provided by NoMA
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,IB,Fullfill the requirments according to chapter 2 Annex XV 2.1 to 2.8 MDR
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,CIP,"CIP shall fulfill the requirements of MDR, Annex XV, chapter II, 3.1 - 3.19 and preferably follow its layout with regards to subtitles."
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,Synopsis,"In Norwegian & in English. Annex XV, chapter II, 3.1.5"
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,Signed statement that the device conforms to regulatory requirements,"Annex XV, chapter II, 4.1 or use the templeate provided by NoMA"
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,MDR Annex XV check list for CIP and IB,Please use the template provided by NoMA
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,GSPRs checklist,Please use the template provided by NoMA
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,Proof of insurance,A copy of the insurance policy or written confirmation from The Norwegian System of Patient Injury Compensation (NPE
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,Documents to be used to obtain informed consent. Including the patient information sheet and the informed consent document. ,Templates are found on the Regional Ethics Committees web site
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,Data protection Statement,
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,Site sustainability ,
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,"PI CVs, GCPs",
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,IF APLICABLE ,From 16 to 19
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,Appendix 2 of aplication Form,If more than one investigational device is involved in the clinical investigation
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,Appendix 3 of Aplication Form,If more than one comparator device is involved in the clinical investigation
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,Opinion from an Expert panel,according to MDR Article 62.2
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,"Documentation according to MDR, Annex XV, chapter II, 2.5","Shall be submitted if the investigational device: -  incorporates a medicinal substance, including a human blood or plasma derivative, or is manufactured utilising non-viable tissues or cells of human or animal origin, or their derivatives"
NO,Norway,Pre-Market,1.0,2022-03-14,Competent Authority,NOTE,"The application is sent by e-mail to  medicininsk.utstyr@legemiddelverket.no . Mark the subject field with «Application for clinical trial of medical equipment», as well as the name of the sponsor and the equipment. On the same day, the application is sent to REK via the REK portal. Documents required by REK are stated on their website . Documents sent to both instances must be identical."
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,COMPULSORY DOCUMENTS,From 1 to 15
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,Documentation requirements and overview of submitted documents (this document),Download from website
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,Cover Letter,Please use the template provided by NoMA
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,Aplication form,Please use the template provided by NoMA
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,Appendix I,Please use the template provided by NoMA
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,IB,Fullfill the requirments according to chapter 2 Annex XV 2.1 to 2.8 MDR
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,CIP,"CIP shall fulfill the requirements of MDR, Annex XV, chapter II, 3.1 - 3.19 and preferably follow its layout with regards to subtitles."
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,Synopsis,"In Norwegian & in English. Annex XV, chapter II, 3.1.5"
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,Signed statement that the device conforms to regulatory requirements,"Annex XV, chapter II, 4.1 or use the templeate provided by NoMA"
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,MDR Annex XV check list for CIP and IB,Please use the template provided by NoMA
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,GSPRs checklist,Please use the template provided by NoMA
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,Proof of insurance,A copy of the insurance policy or written confirmation from The Norwegian System of Patient Injury Compensation (NPE
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,Documents to be used to obtain informed consent. Including the patient information sheet and the informed consent document. ,Templates are found on the Regional Ethics Committees web site
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,Data protection Statement,
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,Site sustainability ,
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,"PI CVs, GCPs",
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,IF APLICABLE ,From 16 to 19
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,Appendix 2 of aplication Form,If more than one investigational device is involved in the clinical investigation
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,Appendix 3 of Aplication Form,If more than one comparator device is involved in the clinical investigation
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,Opinion from an Expert panel,according to MDR Article 62.2
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,"Documentation according to MDR, Annex XV, chapter II, 2.5","Shall be submitted if the investigational device: -  incorporates a medicinal substance, including a human blood or plasma derivative, or is manufactured utilising non-viable tissues or cells of human or animal origin, or their derivatives"
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,Instruction,"The application is sent by e-mail to  medicininsk.utstyr@legemiddelverket.no . Mark the subject field with «Application for clinical trial of medical equipment», as well as the name of the sponsor and the equipment. On the same day, the application is sent to REK via the REK portal. Documents required by REK are stated on their website . Documents sent to both instances must be identical."
NO,Norway,Post-Market,1.0,2022-03-14,Competent Authority,Instruction 2,"The trial can start 30 days after the sponsor submitted the message, unless we inform you otherwise."
PL,Poland,Pre-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Pre-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Pre-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Pre-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Pre-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Pre-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Pre-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Pre-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Pre-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Pre-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Pre-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Pre-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Pre-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Pre-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Pre-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Pre-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Pre-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Pre-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Post-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Post-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Post-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Post-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Post-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Post-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Post-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Post-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Post-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Post-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Post-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Post-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Post-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Post-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Post-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Post-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Post-Market,1.0,2022-03-14,Competent Authority,,
PL,Poland,Post-Market,1.0,2022-03-14,Competent Authority,,
PT,Portugal,Pre-Market,1.0,2022-03-14,Competent Authority,Application for conducting a clinical study with the intervention of medical devices;,
PT,Portugal,Pre-Market,1.0,2022-03-14,Competent Authority,"The ""Notification form relating to medical devices intended for clinical investigations""",
PT,Portugal,Pre-Market,1.0,2022-03-14,Competent Authority,"The ""Declaration Template"" on devices - for pre-market studies involving medical devices.",
PT,Portugal,Pre-Market,1.0,2022-03-14,Competent Authority,Protocols (CIP),
PT,Portugal,Pre-Market,1.0,2022-03-14,Competent Authority,IB,
PT,Portugal,Pre-Market,1.0,2022-03-14,Competent Authority,ICF & Patient information,
PT,Portugal,Pre-Market,1.0,2022-03-14,Competent Authority,Proof of insurance,
PT,Portugal,Pre-Market,1.0,2022-03-14,Competent Authority,IFU and labelling,
PT,Portugal,Pre-Market,1.0,2022-03-14,Competent Authority,Opinion of the EC ,if available at time of submission
PT,Portugal,Pre-Market,1.0,2022-03-14,Competent Authority,"PI CVs, GCPs","updated, signed"
PT,Portugal,Pre-Market,1.0,2022-03-14,Competent Authority,Proof of fee payment,
PT,Portugal,Post-Market,1.0,2022-03-14,Competent Authority,Application for conducting a clinical study with the intervention of medical devices;,Download: https://www.infarmed.pt/web/infarmed/entidades/dispositivos-medicos/investigacao-clinica-avaliacao-funcional/investigacao_clinica
PT,Portugal,Post-Market,1.0,2022-03-14,Competent Authority,"The ""Notification form relating to medical devices intended for clinical investigations""",https://www.infarmed.pt/web/infarmed/entidades/dispositivos-medicos/investigacao-clinica-avaliacao-funcional/investigacao_clinica
PT,Portugal,Post-Market,1.0,2022-03-14,Competent Authority,"The ""Declaration Template"" on devices - for pre-market studies involving medical devices.",https://www.infarmed.pt/web/infarmed/entidades/dispositivos-medicos/investigacao-clinica-avaliacao-funcional/investigacao_clinica
PT,Portugal,Post-Market,1.0,2022-03-14,Competent Authority,Protocols (CIP),
PT,Portugal,Post-Market,1.0,2022-03-14,Competent Authority,IB,
PT,Portugal,Post-Market,1.0,2022-03-14,Competent Authority,ICF & Patient information,
PT,Portugal,Post-Market,1.0,2022-03-14,Competent Authority,Proof of insurance,
PT,Portugal,Post-Market,1.0,2022-03-14,Competent Authority,IFU and labelling,
PT,Portugal,Post-Market,1.0,2022-03-14,Competent Authority,Opinion of the EC ,if available at time of submission
PT,Portugal,Post-Market,1.0,2022-03-14,Competent Authority,"PI CVs, GCPs","updated, signed"
PT,Portugal,Post-Market,1.0,2022-03-14,Competent Authority,Proof of fee payment,
PT,Portugal,Post-Market,1.0,2022-03-14,Competent Authority,Copy of the EC Declaration of Conformity,
PT,Portugal,Post-Market,1.0,2022-03-14,Competent Authority,"Copy of the EC Certificate of Conformity, if applicable",
PT,Portugal,Post-Market,1.0,2022-03-14,Competent Authority,Instruction (See NOTE),"For performing clinical trials in Portugal, sponsors have to get authorization from the Competent Authority and ethical approval from the Ethics Committee (CEIC) plus approval from the National Data Protection Authority (CNPD – “Comissão Nacional de Proteção de Dados”)."
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,"1.1. Name of manufacturer / authorized representative, address, telephone, contact details for communication",
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,1.2. If it is the first request for investigation / evaluation or resolution,
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,"1.3. If there is a recurrence related to the same device, the reference number (s) and previous data from the latest investigations",
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,1.4. Other Member States participating in the clinical investigation / performance evaluation as part of the multinational / multicentre study,
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,1.5. Signed declaration for GSPRs ,
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,"2.1. Device trade name; 2.2. Generic device name; 2.3. Device model name; 2.4. Model number, if any.",
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,"3.1. Classification
3.2. A complete description of the device",
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,3.5. Summary of experiences with any similar device.,
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,3.6 Benefits- risk analysis,
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,3.7. Summary and analysis of preclinical tests and experimental data,
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,3.17. Instructions for use IFU,
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,"4.1. Names, qualifications, professional position, addresses of clinical investigators, coordinating investigator, if any, from multi-center clinical investigation",
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,"4.2. PI CVs, GCPs",
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,4.3. Lists of sites,
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,4.4. Copy of the Ethics Committee's opinion,
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,4.5. Copy of the patient's informed consent,
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,4.6. Copy of the document on how to compensate the patient in case of deterioration of his health following the clinical investigation,
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,"4.7. The summary of the reference scientific literature that was the basis of the study, with analysis and bibliography, if applicable.",
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,CIP ,5.1 to 5.10 
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,6.1. Description of the final results to demonstrate the performance and safety of the use of the device,
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,"6.2. Description of procedures and details of incident recording and reporting,",
RO,Romania,Pre-Market,1.0,2022-03-14,Competent Authority,"6.3. Description and justification of statistical data, analytical method and procedures.",
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,"1.1. Name of manufacturer / authorized representative, address, telephone, contact details for communication",
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,1.2. If it is the first request for investigation / evaluation or resolution,
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,"1.3. If there is a recurrence related to the same device, the reference number (s) and previous data from the latest investigations",
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,1.4. Other Member States participating in the clinical investigation / performance evaluation as part of the multinational / multicentre study,
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,1.5. Signed declaration for GSPRs ,
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,"2.1. Device trade name; 2.2. Generic device name; 2.3. Device model name; 2.4. Model number, if any.",
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,"3.1. Classification
3.2. A complete description of the device",
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,3.5. Summary of experiences with any similar device.,
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,3.6 Benefits- risk analysis,
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,3.7. Summary and analysis of preclinical tests and experimental data,
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,3.17. Instructions for use IFU,
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,"4.1. Names, qualifications, professional position, addresses of clinical investigators, coordinating investigator, if any, from multi-center clinical investigation",
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,"4.2. PI CVs, GCPs",
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,4.3. Lists of sites,
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,4.4. Copy of the Ethics Committee's opinion,
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,4.5. Copy of the patient's informed consent,
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,4.6. Copy of the document on how to compensate the patient in case of deterioration of his health following the clinical investigation,
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,"4.7. The summary of the reference scientific literature that was the basis of the study, with analysis and bibliography, if applicable.",
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,CIP ,5.1 to 5.10 
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,6.1. Description of the final results to demonstrate the performance and safety of the use of the device,
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,"6.2. Description of procedures and details of incident recording and reporting,",
RO,Romania,Post-Market,1.0,2022-03-14,Competent Authority,"6.3. Description and justification of statistical data, analytical method and procedures.",
RS,Unknown,Pre-Market,1.0,2022-03-14,Competent Authority,cover letter;,
RS,Unknown,Pre-Market,1.0,2022-03-14,Competent Authority,request for approval of conducting a clinical trial of a medical device;,
RS,Unknown,Pre-Market,1.0,2022-03-14,Competent Authority,"additional documentation, ie information required as a rule;",
RS,Unknown,Pre-Market,1.0,2022-03-14,Competent Authority,"reasons for categorization, ie classification in accordance with the Law;",
RS,Unknown,Pre-Market,1.0,2022-03-14,Competent Authority,statement and documentation in accordance with Annex 1 Annex VIII and Annex 3 Annex VI of the bylaw which regulates the basic requirements for medical devices;,
RS,Unknown,Pre-Market,1.0,2022-03-14,Competent Authority,other specific information (eg qualifications of the principal investigator and researchers).,
RS,Unknown,Pre-Market,1.0,2022-03-14,Competent Authority,Instruction for more information," Правилник о клиничким испитивањима медицинског средства “Сл. гласник РС”, бр. 91/2018 од 23.11.2018. This document can be downloaded from: https://www.alims.gov.rs/regulativa/medicinska-sredstva/pravilnici/"
RS,Unknown,Post-Market,1.0,2022-03-14,Competent Authority,cover letter;,
RS,Unknown,Post-Market,1.0,2022-03-14,Competent Authority,request for approval of conducting a clinical trial of a medical device;,
RS,Unknown,Post-Market,1.0,2022-03-14,Competent Authority,"additional documentation, ie information required as a rule;",
RS,Unknown,Post-Market,1.0,2022-03-14,Competent Authority,"reasons for categorization, ie classification in accordance with the Law;",
RS,Unknown,Post-Market,1.0,2022-03-14,Competent Authority,statement and documentation in accordance with Annex 1 Annex VIII and Annex 3 Annex VI of the bylaw which regulates the basic requirements for medical devices;,
RS,Unknown,Post-Market,1.0,2022-03-14,Competent Authority,other specific information (eg qualifications of the principal investigator and researchers).,
RS,Unknown,Post-Market,1.0,2022-03-14,Competent Authority,Instruction for more information," Правилник о клиничким испитивањима медицинског средства “Сл. гласник РС”, бр. 91/2018 од 23.11.2018. This document can be downloaded from: https://www.alims.gov.rs/regulativa/medicinska-sredstva/pravilnici/"
SI,Slovenia,Pre-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Competent Authority,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Competent Authority,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Pre-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Pre-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Pre-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Pre-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Pre-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Pre-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Pre-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Pre-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Pre-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Pre-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Pre-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Pre-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Pre-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Pre-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Pre-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Pre-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Pre-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Pre-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Post-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Post-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Post-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Post-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Post-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Post-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Post-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Post-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Post-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Post-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Post-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Post-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Post-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Post-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Post-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Post-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Post-Market,1.0,2022-03-14,Competent Authority,,
SE,Sweden,Post-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Competent Authority,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Competent Authority,,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Competent Authority,,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Competent Authority,,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Competent Authority,,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Competent Authority,,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Competent Authority,,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Competent Authority,,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Competent Authority,,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Competent Authority,,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Competent Authority,,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Competent Authority,,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Competent Authority,,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Competent Authority,,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Competent Authority,,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Competent Authority,,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Competent Authority,,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Competent Authority,,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Competent Authority,,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Competent Authority,,
UK,United Kingdo,Post-Market,1.0,2022-03-14,Competent Authority,Covering letter on headed paper,
UK,United Kingdo,Post-Market,1.0,2022-03-14,Competent Authority,CIP,
UK,United Kingdo,Post-Market,1.0,2022-03-14,Competent Authority,Investigator’s brochure (IB),
UK,United Kingdo,Post-Market,1.0,2022-03-14,Competent Authority,Participant information sheet,
UK,United Kingdo,Post-Market,1.0,2022-03-14,Competent Authority,Participant consent form (ICF),
UK,United Kingdo,Post-Market,1.0,2022-03-14,Competent Authority,"PI CV, GCP",
UK,United Kingdo,Post-Market,1.0,2022-03-14,Competent Authority,Device details,
UK,United Kingdo,Post-Market,1.0,2022-03-14,Competent Authority,Essential requirements checklist (GDPRs),
UK,United Kingdo,Post-Market,1.0,2022-03-14,Competent Authority,Risk analysis,
UK,United Kingdo,Post-Market,1.0,2022-03-14,Competent Authority,IFU,
UK,United Kingdo,Post-Market,1.0,2022-03-14,Competent Authority,Device labels,
UK,United Kingdo,Post-Market,1.0,2022-03-14,Competent Authority,Summary of all bench testing and pre-clinical testing conducted,
UK,United Kingdo,Post-Market,1.0,2022-03-14,Competent Authority,Summary of all clinical experience with the device to date,
UK,United Kingdo,Post-Market,1.0,2022-03-14,Competent Authority,End of study reports for any concluded clinical investigations that involved the same medical device under investigation,
UK,United Kingdo,Post-Market,1.0,2022-03-14,Competent Authority,List of standards met,
UK,United Kingdo,Post-Market,1.0,2022-03-14,Competent Authority,Sterilisation validation report (where relevant),
UK,United Kingdo,Post-Market,1.0,2022-03-14,Competent Authority,Software information (where relevant),
UK,United Kingdo,Post-Market,1.0,2022-03-14,Competent Authority,Biological safety assessments of patient contacting materials (where relevant),
UK,United Kingdo,Post-Market,1.0,2022-03-14,Competent Authority,Information on animal tissues (where relevant),
UK,United Kingdo,Post-Market,1.0,2022-03-14,Competent Authority,"Information on any medicine or human blood derivative, or non-viable human tissues and cells incorporated into the device",
UK,United Kingdo,Post-Market,1.0,2022-03-14,Competent Authority,Research ethics committee opinion (if available),
AT,Austria,Pre-Market,1.0,2022-03-14,Ethics Committee,Receipt of confirmation of EudraCT number,
AT,Austria,Pre-Market,1.0,2022-03-14,Ethics Committee,Cover Letter ,
AT,Austria,Pre-Market,1.0,2022-03-14,Ethics Committee,Application form,Signed and dated 
AT,Austria,Pre-Market,1.0,2022-03-14,Ethics Committee,ICF,"local language, "
AT,Austria,Pre-Market,1.0,2022-03-14,Ethics Committee,subject information leaflet,
AT,Austria,Pre-Market,1.0,2022-03-14,Ethics Committee,Recruitment plan,
AT,Austria,Pre-Market,1.0,2022-03-14,Ethics Committee,Protocols with all amendments ,
AT,Austria,Pre-Market,1.0,2022-03-14,Ethics Committee,Synopsis in local language,
AT,Austria,Pre-Market,1.0,2022-03-14,Ethics Committee,IB,
AT,Austria,Pre-Market,1.0,2022-03-14,Ethics Committee,Summary of the products characteristic,
AT,Austria,Pre-Market,1.0,2022-03-14,Ethics Committee,Centres list ,
AT,Austria,Pre-Market,1.0,2022-03-14,Ethics Committee,"PI CVs, GCPs","updated, signed & dated"
AT,Austria,Pre-Market,1.0,2022-03-14,Ethics Committee,"All other staffs Cvs, GCPs","updated, signed & dated"
AT,Austria,Pre-Market,1.0,2022-03-14,Ethics Committee,Provision of indemnity or compensation,
AT,Austria,Pre-Market,1.0,2022-03-14,Ethics Committee,Proof of Insurance,
AT,Austria,Pre-Market,1.0,2022-03-14,Ethics Committee,Agreement between all parties,
AT,Austria,Post-Market,1.0,2022-03-14,Ethics Committee,Receipt of confirmation of EudraCT number,
AT,Austria,Post-Market,1.0,2022-03-14,Ethics Committee,Cover Letter ,
AT,Austria,Post-Market,1.0,2022-03-14,Ethics Committee,Application form,Signed and dated 
AT,Austria,Post-Market,1.0,2022-03-14,Ethics Committee,ICF,"local language, "
AT,Austria,Post-Market,1.0,2022-03-14,Ethics Committee,subject information leaflet,
AT,Austria,Post-Market,1.0,2022-03-14,Ethics Committee,Recruitment plan,
AT,Austria,Post-Market,1.0,2022-03-14,Ethics Committee,Protocols with all amendments ,
AT,Austria,Post-Market,1.0,2022-03-14,Ethics Committee,Synopsis in local language,
AT,Austria,Post-Market,1.0,2022-03-14,Ethics Committee,IB,
AT,Austria,Post-Market,1.0,2022-03-14,Ethics Committee,Summary of the products characteristic,
AT,Austria,Post-Market,1.0,2022-03-14,Ethics Committee,Centres list ,
AT,Austria,Post-Market,1.0,2022-03-14,Ethics Committee,"PI CVs, GCPs","updated, signed & dated"
AT,Austria,Post-Market,1.0,2022-03-14,Ethics Committee,"All other staffs Cvs, GCPs","updated, signed & dated"
AT,Austria,Post-Market,1.0,2022-03-14,Ethics Committee,Provision of indemnity or compensation,
AT,Austria,Post-Market,1.0,2022-03-14,Ethics Committee,Proof of Insurance,
AT,Austria,Post-Market,1.0,2022-03-14,Ethics Committee,Agreement between all parties,
BY,Belarus,Pre-Market,1.0,2022-03-14,Ethics Committee,Register the device in the national system,Download form on webpgae. https://rceth.by/ru/Documents/Med/1 
BY,Belarus,Pre-Market,1.0,2022-03-14,Ethics Committee,Guide for researcher= IB,
BY,Belarus,Pre-Market,1.0,2022-03-14,Ethics Committee,Protocol & amendments ,Dated and signed
BY,Belarus,Pre-Market,1.0,2022-03-14,Ethics Committee,ICF in local language,
BY,Belarus,Pre-Market,1.0,2022-03-14,Ethics Committee,Subjects recruiment,
BY,Belarus,Pre-Market,1.0,2022-03-14,Ethics Committee,Documents on the financial aspect,
BY,Belarus,Pre-Market,1.0,2022-03-14,Ethics Committee,Proof of Insurance,
BY,Belarus,Pre-Market,1.0,2022-03-14,Ethics Committee,Agreement between the parties,
BY,Belarus,Pre-Market,1.0,2022-03-14,Ethics Committee,Permission to conduct a clinical trial,
BY,Belarus,Pre-Market,1.0,2022-03-14,Ethics Committee,"PI & other staffs Cvs, GCPs",
BY,Belarus,Pre-Market,1.0,2022-03-14,Ethics Committee,IFU ,
BY,Belarus,Pre-Market,1.0,2022-03-14,Ethics Committee,Invoices (postal receipts) for the supply of the investigated medical device and medical equipment,
BY,Belarus,Post-Market,1.0,2022-03-14,Ethics Committee,Register the device in the national system,Download form on webpgae. https://rceth.by/ru/Documents/Med/1 
BY,Belarus,Post-Market,1.0,2022-03-14,Ethics Committee,Guide for researcher= IB,
BY,Belarus,Post-Market,1.0,2022-03-14,Ethics Committee,Protocol & amendments ,Dated and signed
BY,Belarus,Post-Market,1.0,2022-03-14,Ethics Committee,ICF in local language,
BY,Belarus,Post-Market,1.0,2022-03-14,Ethics Committee,Subjects recruiment,
BY,Belarus,Post-Market,1.0,2022-03-14,Ethics Committee,Documents on the financial aspect,
BY,Belarus,Post-Market,1.0,2022-03-14,Ethics Committee,Proof of Insurance,
BY,Belarus,Post-Market,1.0,2022-03-14,Ethics Committee,Agreement between the parties,
BY,Belarus,Post-Market,1.0,2022-03-14,Ethics Committee,Permission to conduct a clinical trial,
BY,Belarus,Post-Market,1.0,2022-03-14,Ethics Committee,"PI & other staffs Cvs, GCPs",
BY,Belarus,Post-Market,1.0,2022-03-14,Ethics Committee,IFU ,
BY,Belarus,Post-Market,1.0,2022-03-14,Ethics Committee,Invoices (postal receipts) for the supply of the investigated medical device and medical equipment,
BY,Belarus,Post-Market,1.0,2022-03-14,Ethics Committee,,
BE,Belgium,Pre-Market,1.0,2022-03-14,Ethics Committee,COVER LETTER,It should be clearly mentioned which Belgian regulatory pathway is applicable: Consolidated opinion FAMHP and EC 
BE,Belgium,Pre-Market,1.0,2022-03-14,Ethics Committee,List of documents submitted ,Template on website
BE,Belgium,Pre-Market,1.0,2022-03-14,Ethics Committee,APPLICATION FORM,Template on website
BE,Belgium,Pre-Market,1.0,2022-03-14,Ethics Committee,"CIP (with Annexes, version and date)",
BE,Belgium,Pre-Market,1.0,2022-03-14,Ethics Committee,Synopsis,
BE,Belgium,Pre-Market,1.0,2022-03-14,Ethics Committee,INVESTIGATOR’S BROCHURE (With annexes),
BE,Belgium,Pre-Market,1.0,2022-03-14,Ethics Committee,Example of labels,
BE,Belgium,Pre-Market,1.0,2022-03-14,Ethics Committee,LIST OF GENERAL SAFETY AND PERFORMANCE REQUIREMENTS,Template on website
BE,Belgium,Pre-Market,1.0,2022-03-14,Ethics Committee,MANUFACTURER’S IFU,
BE,Belgium,Pre-Market,1.0,2022-03-14,Ethics Committee,CLINICAL EVALUATION PLAN,
BE,Belgium,Pre-Market,1.0,2022-03-14,Ethics Committee,PROOF OF INSURANCE,
BE,Belgium,Pre-Market,1.0,2022-03-14,Ethics Committee,"PI Cvs, GCPs, & DOI ",
BE,Belgium,Pre-Market,1.0,2022-03-14,Ethics Committee,SUITABILITY OF SITE(S),
BE,Belgium,Pre-Market,1.0,2022-03-14,Ethics Committee,Agreements between parties,
BE,Belgium,Pre-Market,1.0,2022-03-14,Ethics Committee,RECRUITMENT AND ADVERTISING,
BE,Belgium,Pre-Market,1.0,2022-03-14,Ethics Committee,"PATIENT INFO, ICF AND ICF PROCEDURE",
BE,Belgium,Pre-Market,1.0,2022-03-14,Ethics Committee,FINANCIAL AND OTHER ARRANGEMENTS,
BE,Belgium,Pre-Market,1.0,2022-03-14,Ethics Committee,STATEMENT ON DATA PROTECTION,
BE,Belgium,Pre-Market,1.0,2022-03-14,Ethics Committee,"If multinational, status on submission procedure(s) in other countries, including any approval or refusal letter if applicable.",
BE,Belgium,Pre-Market,1.0,2022-03-14,Ethics Committee,CE certificate and manufacturer’s instructions for use of any comparator device used,
BE,Belgium,Post-Market,1.0,2022-03-14,Ethics Committee,COVER LETTER (Accusé de réception = AOR ),It should be clearly mentioned which Belgian regulatory pathway is applicable: EC ONLY
BE,Belgium,Post-Market,1.0,2022-03-14,Ethics Committee,Avis du Comité d’Ethique ,
BE,Belgium,Post-Market,1.0,2022-03-14,Ethics Committee,Questionnaire type ,
BE,Belgium,Post-Market,1.0,2022-03-14,Ethics Committee,Letter of advice from the Central Committee.,
BE,Belgium,Post-Market,1.0,2022-03-14,Ethics Committee,Synopsis,In French. Max 3 pages
BE,Belgium,Post-Market,1.0,2022-03-14,Ethics Committee,Informed Consent Form ICF,In French compulsory. Other languages such as English & Dutch also available.
BE,Belgium,Post-Market,1.0,2022-03-14,Ethics Committee,PROOF OF INSURANCE,The certificate must specify the expiry date of the insurance.
BE,Belgium,Post-Market,1.0,2022-03-14,Ethics Committee,Receipt of payment,
BE,Belgium,Post-Market,1.0,2022-03-14,Ethics Committee,RECRUITMENT AND ADVERTISING,
BE,Belgium,Post-Market,1.0,2022-03-14,Ethics Committee,CIP with amendments,Signed & dated by the investigator
BE,Belgium,Post-Market,1.0,2022-03-14,Ethics Committee,Contact details for the Central Ethics Committee and sites participating in the study,"Contact persons: e-mail addresses, addresses and telephone numbers."
BE,Belgium,Post-Market,1.0,2022-03-14,Ethics Committee,"INVESTIGATOR(S) CV, GCPs",
BE,Belgium,Post-Market,1.0,2022-03-14,Ethics Committee,Declaration of conflict of interest,dated and signed by all local investigators
BE,Belgium,Post-Market,1.0,2022-03-14,Ethics Committee,FINANCIAL Agreements between the parties,
BE,Belgium,Post-Market,1.0,2022-03-14,Ethics Committee,IB ,
BE,Belgium,Post-Market,1.0,2022-03-14,Ethics Committee,CE Certificates,
BE,Belgium,Post-Market,1.0,2022-03-14,Ethics Committee,Instruction for sending documents,"(digital version and paper version), with all the required documents (specified versions and dates).
Some documents are to be provided in digital version; others are to be provided in digital version AND in paper version (6 copies).
Digital documents must be sent:
• Either by e-mail: comite.ethique@ghdc.be
• Or by e-mail via a eudralink link
• Either on cd-rom, by post, to the following address: GHdC – Site Saint Joseph
Comité d’Ethique
Rue Marguerite Depasse 6
6060 GILLY "
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Ethics Committee,Cover Letter,
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Ethics Committee,Application Form (download from web),
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Ethics Committee,Administrative information (Download form) ,"Art. 2 of Regulation No10, 2008, of Ministry of Health"
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Ethics Committee,Participant information,Art 3 
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Ethics Committee,CIP,Art 4
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Ethics Committee,Device information,Art 5
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Ethics Committee,Documentation about medical institution technical resources and profecional qualification of investigating team,
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Ethics Committee,"PI CV, GCP",Art 6
BG,Bulgaria,Pre-Market,1.0,2022-03-14,Ethics Committee,Financial source and administrative management ,Art 7
BG,Bulgaria,Post-Market,1.0,2022-03-14,Ethics Committee,Cover Letter,
BG,Bulgaria,Post-Market,1.0,2022-03-14,Ethics Committee,Application Form (download from web),
BG,Bulgaria,Post-Market,1.0,2022-03-14,Ethics Committee,Administrative information (Download form) ,"Art. 2 of Regulation No10, 2008, of Ministry of Health"
BG,Bulgaria,Post-Market,1.0,2022-03-14,Ethics Committee,Participant information,Art 3 
BG,Bulgaria,Post-Market,1.0,2022-03-14,Ethics Committee,CIP,Art 4
BG,Bulgaria,Post-Market,1.0,2022-03-14,Ethics Committee,Device information,Art 5
BG,Bulgaria,Post-Market,1.0,2022-03-14,Ethics Committee,Documentation about medical institution technical resources and profecional qualification of investigating team,
BG,Bulgaria,Post-Market,1.0,2022-03-14,Ethics Committee,"PI CV, GCP",Art 6
BG,Bulgaria,Post-Market,1.0,2022-03-14,Ethics Committee,Financial source and administrative management ,Art 7
CH,Switzerland,Pre-Market,1.0,2022-03-14,Ethics Committee,Cover Letter ,
CH,Switzerland,Pre-Market,1.0,2022-03-14,Ethics Committee,Synopsis,Muticentric: Language of Lead EC or in English. Monocentric: Languge of EC. Template available
CH,Switzerland,Pre-Market,1.0,2022-03-14,Ethics Committee,Participants information & ICF,Template available
CH,Switzerland,Pre-Market,1.0,2022-03-14,Ethics Committee,Protocols,Signed & dated
CH,Switzerland,Pre-Market,1.0,2022-03-14,Ethics Committee,Monitoring plan (if available),
CH,Switzerland,Pre-Market,1.0,2022-03-14,Ethics Committee,CRF,Draft accepted. Final document within the next 30 days. 
CH,Switzerland,Pre-Market,1.0,2022-03-14,Ethics Committee,"PI Cvs, GCPs",
CH,Switzerland,Pre-Market,1.0,2022-03-14,Ethics Committee,Site sustainability,
CH,Switzerland,Pre-Market,1.0,2022-03-14,Ethics Committee,Agreements between the parties,Template available
CH,Switzerland,Pre-Market,1.0,2022-03-14,Ethics Committee,"Recruitment plan , questionnaires…",
CH,Switzerland,Pre-Market,1.0,2022-03-14,Ethics Committee,Details on compensations,
CH,Switzerland,Pre-Market,1.0,2022-03-14,Ethics Committee,Other personnels,Template available online
CH,Switzerland,Pre-Market,1.0,2022-03-14,Ethics Committee,Information on handling personal Data,
CH,Switzerland,Pre-Market,1.0,2022-03-14,Ethics Committee,"Information on reviews of this proposal by other Ethics Committees, or Regulatory Authorities (Foreign or Swiss)",If aplicable
CH,Switzerland,Pre-Market,1.0,2022-03-14,Ethics Committee,"Sponsor Delegation Letter, signed",
CH,Switzerland,Pre-Market,1.0,2022-03-14,Ethics Committee,Extra for each local EC:  Evidence/Statement from the sponsor on the ability to conduct the clinical investigation ,
CH,Switzerland,Post-Market,1.0,2022-03-14,Ethics Committee,Cover Letter ,
CH,Switzerland,Post-Market,1.0,2022-03-14,Ethics Committee,Synopsis,Muticentric: Language of Lead EC or in English. Monocentric: Languge of EC. Template available
CH,Switzerland,Post-Market,1.0,2022-03-14,Ethics Committee,Participants information & ICF,Template available
CH,Switzerland,Post-Market,1.0,2022-03-14,Ethics Committee,Protocols,Signed & dated
CH,Switzerland,Post-Market,1.0,2022-03-14,Ethics Committee,Monitoring plan (if available),
CH,Switzerland,Post-Market,1.0,2022-03-14,Ethics Committee,CRF,Draft accepted. Final document within the next 30 days. 
CH,Switzerland,Post-Market,1.0,2022-03-14,Ethics Committee,"PI Cvs, GCPs",
CH,Switzerland,Post-Market,1.0,2022-03-14,Ethics Committee,Site sustainability,
CH,Switzerland,Post-Market,1.0,2022-03-14,Ethics Committee,Agreements between the parties,Template available
CH,Switzerland,Post-Market,1.0,2022-03-14,Ethics Committee,"Recruitment plan , questionnaires…",
CH,Switzerland,Post-Market,1.0,2022-03-14,Ethics Committee,Details on compensations,
CH,Switzerland,Post-Market,1.0,2022-03-14,Ethics Committee,Other personnels,Template available online
CH,Switzerland,Post-Market,1.0,2022-03-14,Ethics Committee,Information on handling personal Data,
CH,Switzerland,Post-Market,1.0,2022-03-14,Ethics Committee,"Information on reviews of this proposal by other Ethics Committees, or Regulatory Authorities (Foreign or Swiss)",If aplicable
CH,Switzerland,Post-Market,1.0,2022-03-14,Ethics Committee,"Sponsor Delegation Letter, signed",
CH,Switzerland,Post-Market,1.0,2022-03-14,Ethics Committee,Extra for each local EC:  Evidence/Statement from the sponsor on the ability to conduct the clinical investigation ,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Ethics Committee,Register as a user of the SEP Online database,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Ethics Committee,Cover Letter,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Ethics Committee,Protocol Summary Form (Test plan),
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Ethics Committee,Signed signature page of the valid version of the test plan by the new examiner,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Ethics Committee,Confirmation of the payment ,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Ethics Committee,"PI and Monitor Cvs, GCP (download form)","In Crotian, following the form. Signed and dated, updated no older than 6 months. Lead PI should have done at least 3 clinical trials, one of those has phase III. Download from: https://www.halmed.hr/en/O-HALMED-u/Sredisnje-eticko-povjerenstvo-SEP/Naputci-podnositeljima-zahtjeva/ "
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Ethics Committee,Financial plan/ signed contract with the distribution of funds between the institution and the examiner,"he amount of compensation to a legal entity and the examination team for visits is distributed in the ratio of 40% to the legal entity and 60% to the investigative team. team in case the institution has an established organizational unit for clinical trials, otherwise, the amount of compensation is distributed in the ratio of 20% to the legal entity and 80% to the research team"
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Ethics Committee,Proof of insurance,In Croatian. 
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Ethics Committee,ICF ,
CR,Costa Rica,Pre-Market,1.0,2022-03-14,Ethics Committee,Instruction for submission ,"Fill in the form and send it, signed and stamped by the responsible person of the applicant to IT Unit or to CEC per post to: Agency for Medicinal Products and Medical Devices of Croatia, Ksaverska cesta 4, 10 000 Zagreb, Republic of Croatia or personally to HALMED's Registry Office."
CR,Costa Rica,Post-Market,1.0,2022-03-14,Ethics Committee,Register as a user of the SEP Online database,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Ethics Committee,Cover Letter,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Ethics Committee,Protocol Summary Form (Test plan),
CR,Costa Rica,Post-Market,1.0,2022-03-14,Ethics Committee,Signed signature page of the valid version of the test plan by the new examiner,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Ethics Committee,Confirmation of the payment ,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Ethics Committee,"PI and Monitor Cvs, GCP (download form)","In Crotian, following the form. Signed and dated, updated no older than 6 months. Lead PI should have done at least 3 clinical trials, one of those has phase III. Download from:  https://www.halmed.hr/en/O-HALMED-u/Sredisnje-eticko-povjerenstvo-SEP/Naputci-podnositeljima-zahtjeva/ "
CR,Costa Rica,Post-Market,1.0,2022-03-14,Ethics Committee,Financial plan/ signed contract with the distribution of funds between the institution and the examiner,"he amount of compensation to a legal entity and the examination team for visits is distributed in the ratio of 40% to the legal entity and 60% to the investigative team. team in case the institution has an established organizational unit for clinical trials, otherwise, the amount of compensation is distributed in the ratio of 20% to the legal entity and 80% to the research team"
CR,Costa Rica,Post-Market,1.0,2022-03-14,Ethics Committee,Proof of insurance,In Croatian. 
CR,Costa Rica,Post-Market,1.0,2022-03-14,Ethics Committee,ICF ,
CR,Costa Rica,Post-Market,1.0,2022-03-14,Ethics Committee,Instruction for submission ,"Fill in the form and send it, signed and stamped by the responsible person of the applicant to IT Unit or to CEC per post to: Agency for Medicinal Products and Medical Devices of Croatia, Ksaverska cesta 4, 10 000 Zagreb, Republic of Croatia or personally to HALMED's Registry Office."
CY,Cyprus,Pre-Market,1.0,2022-03-14,Ethics Committee,Cover Letter,
CY,Cyprus,Pre-Market,1.0,2022-03-14,Ethics Committee,EEBK02 (Application for Program Approval) download,Page 11 to 13 not for MDs
CY,Cyprus,Pre-Market,1.0,2022-03-14,Ethics Committee,EEBK03 (Consent Form)/ Assent Form if aplicable,
CY,Cyprus,Pre-Market,1.0,2022-03-14,Ethics Committee,The Research Proposal (CIP),
CY,Cyprus,Pre-Market,1.0,2022-03-14,Ethics Committee,The Project budgets,
CY,Cyprus,Pre-Market,1.0,2022-03-14,Ethics Committee,The Insurance Contract (where applicable),
CY,Cyprus,Pre-Market,1.0,2022-03-14,Ethics Committee,The sponsor approval agreement ,
CY,Cyprus,Pre-Market,1.0,2022-03-14,Ethics Committee,Proof of payment of the relevant bioethics fee evaluation.,
CY,Cyprus,Pre-Market,1.0,2022-03-14,Ethics Committee,"PI CVs (max 2 pages), GCPs",
CY,Cyprus,Pre-Market,1.0,2022-03-14,Ethics Committee,"Recruitment information (advertisements, flyers…)",
CY,Cyprus,Pre-Market,1.0,2022-03-14,Ethics Committee,Instruction for submission ,NOTE: EBs will handle applications submitted at least 3 weeks prior to the date of their regular meetings.
CY,Cyprus,Post-Market,1.0,2022-03-14,Ethics Committee,Cover Letter,
CY,Cyprus,Post-Market,1.0,2022-03-14,Ethics Committee,EEBK02 (Application for Program Approval) download,Page 11 to 13 not for MDs
CY,Cyprus,Post-Market,1.0,2022-03-14,Ethics Committee,EEBK03 (Consent Form)/ Assent Form if aplicable,
CY,Cyprus,Post-Market,1.0,2022-03-14,Ethics Committee,The Research Proposal (CIP),
CY,Cyprus,Post-Market,1.0,2022-03-14,Ethics Committee,The Project budgets,
CY,Cyprus,Post-Market,1.0,2022-03-14,Ethics Committee,The Insurance Contract (where applicable),
CY,Cyprus,Post-Market,1.0,2022-03-14,Ethics Committee,The sponsor approval agreement ,
CY,Cyprus,Post-Market,1.0,2022-03-14,Ethics Committee,Proof of payment of the relevant bioethics fee evaluation.,
CY,Cyprus,Post-Market,1.0,2022-03-14,Ethics Committee,"PI CVs (max 2 pages), GCPs",
CY,Cyprus,Post-Market,1.0,2022-03-14,Ethics Committee,"Recruitment information (advertisements, flyers…)",
CY,Cyprus,Post-Market,1.0,2022-03-14,Ethics Committee,Instruction for submission ,NOTE: EBs will handle applications submitted at least 3 weeks prior to the date of their regular meetings.
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Ethics Committee,written contract between the sponsor of the clinical investigation and the provider of healthcare services,
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Ethics Committee,a written contract between the sponsor of the clinical investigation and the investigator,
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Ethics Committee,Investigator's Brochure,
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Ethics Committee,CIP,
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Ethics Committee,ICF,Section 18 Act on MDs
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Ethics Committee,Insurance Cerificate,
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Ethics Committee,A declaration as to whether the medical device contains an active substance or a human blood or plasma derivative as its integral part,
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Ethics Committee,"declaration as to whether the medical device, with a view to minimising the risks of TSE infection transfer to humans, has been manufactured using tissues of animal origin (if aplicable)",
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Ethics Committee,declaration that the concerned medical device meets basic requirements set forth for medical devices in conformity assessment (CE Certificate),
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Ethics Committee,Device information ,
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Ethics Committee,"PI CVs, GCP",
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Ethics Committee,Clinical Trial Agreement (CTA),
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Ethics Committee,Economic compensation (if Applicable),
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Ethics Committee,Payment detail ,
CZ,Czech Republic,Pre-Market,1.0,2022-03-14,Ethics Committee,Sponsor Letter ,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Ethics Committee,written contract between the sponsor of the clinical investigation and the provider of healthcare services,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Ethics Committee,a written contract between the sponsor of the clinical investigation and the investigator,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Ethics Committee,Investigator's Brochure,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Ethics Committee,CIP,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Ethics Committee,ICF,Section 18 Act on MDs
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Ethics Committee,Insurance Cerificate,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Ethics Committee,A declaration as to whether the medical device contains an active substance or a human blood or plasma derivative as its integral part,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Ethics Committee,"declaration as to whether the medical device, with a view to minimising the risks of TSE infection transfer to humans, has been manufactured using tissues of animal origin (if aplicable)",
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Ethics Committee,declaration that the concerned medical device meets basic requirements set forth for medical devices in conformity assessment (CE Certificate),
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Ethics Committee,Device information ,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Ethics Committee,"PI CVs, GCP",
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Ethics Committee,Clinical Trial Agreement (CTA),
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Ethics Committee,Economic compensation (if Applicable),
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Ethics Committee,Payment detail ,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Ethics Committee,Sponsor Letter ,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Ethics Committee,,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Ethics Committee,,
CZ,Czech Republic,Post-Market,1.0,2022-03-14,Ethics Committee,,
DK,Denmark,Pre-Market,1.0,2022-03-14,Ethics Committee,SAME TO BOTH EC & CA,
DK,Denmark,Pre-Market,1.0,2022-03-14,Ethics Committee,“01.01 Cover letter”,
DK,Denmark,Pre-Market,1.0,2022-03-14,Ethics Committee,“01.02 Application form”,Aplication Form for Pre-Market
DK,Denmark,Pre-Market,1.0,2022-03-14,Ethics Committee,“02.01 Investigator Brocure”,
DK,Denmark,Pre-Market,1.0,2022-03-14,Ethics Committee,“02.02 Instruction for use”,
DK,Denmark,Pre-Market,1.0,2022-03-14,Ethics Committee,“02.03 Checklist for fulfilment of general safety performance requirements”,
DK,Denmark,Pre-Market,1.0,2022-03-14,Ethics Committee,“03.01 Clinical investigation plan”,
DK,Denmark,Pre-Market,1.0,2022-03-14,Ethics Committee,Patient information(s) and informed consent form(s),“04.01 Subject information and consent form patients”                                                                           “04.02 Subject information and consent form legal representative”; 04.03 and so on 
DK,Denmark,Pre-Market,1.0,2022-03-14,Ethics Committee,Statement certifying that the device in question complies with the General safety and performance requirements,“05.01 Statement of compliance”
DK,Denmark,Pre-Market,1.0,2022-03-14,Ethics Committee,GDPR Data protection ,“06.01 sponsors statement on how to comply with GDPR”; 06.02… 
DK,Denmark,Pre-Market,1.0,2022-03-14,Ethics Committee,Extra information (See note),Send documents to both EC & CA. 
DK,Denmark,Pre-Market,1.0,2022-03-14,Ethics Committee,REQUIRED FROM EC,
DK,Denmark,Pre-Market,1.0,2022-03-14,Ethics Committee,Synopsis,In Danish. File name 07.01
DK,Denmark,Pre-Market,1.0,2022-03-14,Ethics Committee,CRF and questionnaires,File name 08.01; 08.02… 
DK,Denmark,Pre-Market,1.0,2022-03-14,Ethics Committee,Recruitment plan ,"For example, advertisements, notices, recruitment letters, text on www.sundhed.dk or social media.  File name 09.01"
DK,Denmark,Pre-Market,1.0,2022-03-14,Ethics Committee,Proof of insurance,See guidance on insurance: www.nvk.dk/emner/forsikring-og-erstatning/vejledning-om-forsikring. File name 10.01
DK,Denmark,Pre-Market,1.0,2022-03-14,Ethics Committee,Danish version of relevant parts of sponsorship contract,File name 11.01; 11.02… 
DK,Denmark,Pre-Market,1.0,2022-03-14,Ethics Committee,CE marking (not in pre-market),File name 12.01
DK,Denmark,Pre-Market,1.0,2022-03-14,Ethics Committee,"PI information, including CV, GCP, copy of ID, other diploma, & either health card, passport, driver's license ","File name 13.01, 13.02, 13.03…"
DK,Denmark,Pre-Market,1.0,2022-03-14,Ethics Committee,"Sponsor information,  including company address & CVR No, Contact form.","File name 14.01, 14.02"
DK,Denmark,Pre-Market,1.0,2022-03-14,Ethics Committee,Billing information ,Link to form:  www.dvmk.dk/ansoger/gebyrer. The invoicing form must be signed and attached to the application at the same time as submitting the application. File name 15.01
DK,Denmark,Post-Market,1.0,2022-03-14,Ethics Committee,SAME TO BOTH EC & CA,
DK,Denmark,Post-Market,1.0,2022-03-14,Ethics Committee,“01.01 Cover letter”,
DK,Denmark,Post-Market,1.0,2022-03-14,Ethics Committee,“01.02 Application form”,Aplication Form for Pre-Market
DK,Denmark,Post-Market,1.0,2022-03-14,Ethics Committee,“02.01 Investigator Brocure”,
DK,Denmark,Post-Market,1.0,2022-03-14,Ethics Committee,“02.02 Instruction for use”,
DK,Denmark,Post-Market,1.0,2022-03-14,Ethics Committee,“02.03 Checklist for fulfilment of general safety performance requirements”,
DK,Denmark,Post-Market,1.0,2022-03-14,Ethics Committee,“03.01 Clinical investigation plan”,
DK,Denmark,Post-Market,1.0,2022-03-14,Ethics Committee,Patient information(s) and informed consent form(s),“04.01 Subject information and consent form patients”                                                                           “04.02 Subject information and consent form legal representative”; 04.03 and so on 
DK,Denmark,Post-Market,1.0,2022-03-14,Ethics Committee,Statement certifying that the device in question complies with the General safety and performance requirements,“05.01 Statement of compliance”
DK,Denmark,Post-Market,1.0,2022-03-14,Ethics Committee,GDPR Data protection ,“06.01 sponsors statement on how to comply with GDPR”; 06.02… 
DK,Denmark,Post-Market,1.0,2022-03-14,Ethics Committee,Extra information (See note),Send documents to both EC & CA. 
DK,Denmark,Post-Market,1.0,2022-03-14,Ethics Committee,REQUIRED FROM EC,
DK,Denmark,Post-Market,1.0,2022-03-14,Ethics Committee,Synopsis,In Danish. File name 07.01
DK,Denmark,Post-Market,1.0,2022-03-14,Ethics Committee,CRF and questionnaires,File name 08.01; 08.02… 
DK,Denmark,Post-Market,1.0,2022-03-14,Ethics Committee,Recruitment plan ,"For example, advertisements, notices, recruitment letters, text on www.sundhed.dk or social media.  File name 09.01"
DK,Denmark,Post-Market,1.0,2022-03-14,Ethics Committee,Proof of insurance,See guidance on insurance: www.nvk.dk/emner/forsikring-og-erstatning/vejledning-om-forsikring. File name 10.01
DK,Denmark,Post-Market,1.0,2022-03-14,Ethics Committee,Danish version of relevant parts of sponsorship contract,File name 11.01; 11.02… 
DK,Denmark,Post-Market,1.0,2022-03-14,Ethics Committee,CE marking ,File name 12.01
DK,Denmark,Post-Market,1.0,2022-03-14,Ethics Committee,"PI information, including CV, GCP, copy of ID, other diploma, & either health card, passport, driver's license ","File name 13.01, 13.02, 13.03…"
DK,Denmark,Post-Market,1.0,2022-03-14,Ethics Committee,"Sponsor information,  including company address & CVR No, Contact form.","File name 14.01, 14.02"
DK,Denmark,Post-Market,1.0,2022-03-14,Ethics Committee,Billing information ,Link to form:  www.dvmk.dk/ansoger/gebyrer. The invoicing form must be signed and attached to the application at the same time as submitting the application. File name 15.01
DE,Germany,Pre-Market,1.0,2022-03-14,Ethics Committee,Formal description of the content (FIB in German),
DE,Germany,Pre-Market,1.0,2022-03-14,Ethics Committee,CIP,
DE,Germany,Pre-Market,1.0,2022-03-14,Ethics Committee,Synopsis in DE,
DE,Germany,Pre-Market,1.0,2022-03-14,Ethics Committee,ICF,
DE,Germany,Pre-Market,1.0,2022-03-14,Ethics Committee,Extra information on the submission (see notes),
DE,Germany,Pre-Market,1.0,2022-03-14,Ethics Committee,Investigators list (with CVs),
DE,Germany,Pre-Market,1.0,2022-03-14,Ethics Committee,Power of attorney form (Formular Vollmacht),
DE,Germany,Pre-Market,1.0,2022-03-14,Ethics Committee,Declaration of cost coverage (Kostenübernahmeerklärung),
DE,Germany,Pre-Market,1.0,2022-03-14,Ethics Committee,"CTA
","(Angaben zur Finanzierung dieses Projektes und zur Vergütung der teilnehmenden Ärzte, welche eine Beurteilung der Angemessenheit von Vergütung und erbrachter Leistung ermöglichen)"
DE,Germany,Pre-Market,1.0,2022-03-14,Ethics Committee,Sponsor delegation of authority,
DE,Germany,Pre-Market,1.0,2022-03-14,Ethics Committee,EC Certificate Annex II G1 Rev 02,
DE,Germany,Pre-Market,1.0,2022-03-14,Ethics Committee,ISO 13485 0001 Q5 Rev 02,
DE,Germany,Pre-Market,1.0,2022-03-14,Ethics Committee,IFU,
DE,Germany,Pre-Market,1.0,2022-03-14,Ethics Committee,Extra information on the submission (see notes),When we have to provide the documentation: 10 working days before EC meeting
DE,Germany,Post-Market,1.0,2022-03-14,Ethics Committee,Formal description of the content (FIB in German),
DE,Germany,Post-Market,1.0,2022-03-14,Ethics Committee,CIP,
DE,Germany,Post-Market,1.0,2022-03-14,Ethics Committee,Synopsis in DE,
DE,Germany,Post-Market,1.0,2022-03-14,Ethics Committee,ICF,
DE,Germany,Post-Market,1.0,2022-03-14,Ethics Committee,Extra information on the submission (see notes),
DE,Germany,Post-Market,1.0,2022-03-14,Ethics Committee,Investigators list (with CVs),
DE,Germany,Post-Market,1.0,2022-03-14,Ethics Committee,Power of attorney form (Formular Vollmacht),
DE,Germany,Post-Market,1.0,2022-03-14,Ethics Committee,Declaration of cost coverage (Kostenübernahmeerklärung),
DE,Germany,Post-Market,1.0,2022-03-14,Ethics Committee,"CTA
","(Angaben zur Finanzierung dieses Projektes und zur Vergütung der teilnehmenden Ärzte, welche eine Beurteilung der Angemessenheit von Vergütung und erbrachter Leistung ermöglichen)"
DE,Germany,Post-Market,1.0,2022-03-14,Ethics Committee,Sponsor delegation of authority,
DE,Germany,Post-Market,1.0,2022-03-14,Ethics Committee,EC Certificate Annex II G1 Rev 02,
DE,Germany,Post-Market,1.0,2022-03-14,Ethics Committee,ISO 13485 0001 Q5 Rev 02,
DE,Germany,Post-Market,1.0,2022-03-14,Ethics Committee,IFU,
DE,Germany,Post-Market,1.0,2022-03-14,Ethics Committee,Extra information on the submission (see notes),When we have to provide the documentation: 10 working days before EC meeting
DE,Germany,Post-Market,1.0,2022-03-14,Ethics Committee,,
DE,Germany,Post-Market,1.0,2022-03-14,Ethics Committee,,
DE,Germany,Post-Market,1.0,2022-03-14,Ethics Committee,,
DE,Germany,Post-Market,1.0,2022-03-14,Ethics Committee,,
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,MANDATORY,
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,Cover Letter,
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,Aplication Form ,Download from web
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,IB,Including annexes 
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,CIP,
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,CEP,
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,Synopsis,
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,Statement of conformity,
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,Example of labels,
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,Description of the arrangements to comply with the applicable rules on the protection and confidentiality of personal data/ personal information,
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,List of GSPRs ,
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,AS APLICABLE,
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,Description of the arrangements to comply with the applicable rules on the protection and confidentiality of personal data/ personal information,
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,Risk management,
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,Test reports,
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,Proof of clinical Insurance,
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,Suitability of investigational sites and investigation site team,
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,Manufacturer's IFU,
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,"PI CVs, GCPs",
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,Recruitment procedures,
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,ICF & related documentation,
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,CE certificate,
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,Decisions from other countries,
EE,Estonia,Pre-Market,1.0,2022-03-14,Ethics Committee,PMCF Plan,
EE,Estonia,Post-Market,1.0,2022-03-14,Ethics Committee,,
EE,Estonia,Post-Market,1.0,2022-03-14,Ethics Committee,,
EE,Estonia,Post-Market,1.0,2022-03-14,Ethics Committee,,
EE,Estonia,Post-Market,1.0,2022-03-14,Ethics Committee,,
EE,Estonia,Post-Market,1.0,2022-03-14,Ethics Committee,,
EE,Estonia,Post-Market,1.0,2022-03-14,Ethics Committee,,
EE,Estonia,Post-Market,1.0,2022-03-14,Ethics Committee,,
EE,Estonia,Post-Market,1.0,2022-03-14,Ethics Committee,,
EE,Estonia,Post-Market,1.0,2022-03-14,Ethics Committee,,
EE,Estonia,Post-Market,1.0,2022-03-14,Ethics Committee,,
EE,Estonia,Post-Market,1.0,2022-03-14,Ethics Committee,,
EE,Estonia,Post-Market,1.0,2022-03-14,Ethics Committee,,
EE,Estonia,Post-Market,1.0,2022-03-14,Ethics Committee,,
EE,Estonia,Post-Market,1.0,2022-03-14,Ethics Committee,,
EE,Estonia,Post-Market,1.0,2022-03-14,Ethics Committee,,
EE,Estonia,Post-Market,1.0,2022-03-14,Ethics Committee,,
EE,Estonia,Post-Market,1.0,2022-03-14,Ethics Committee,,
EE,Estonia,Post-Market,1.0,2022-03-14,Ethics Committee,,
ES,Spain,Pre-Market,1.0,2022-03-14,Ethics Committee,Cover Letter ,"Evaluation of protocols, signed by sponsor/PI, indicating code & title of study. Indicate the pathway of EC evaluation (pre or post market), & the lists of participating centers. Writing the lists of documents that will be submitted"
ES,Spain,Pre-Market,1.0,2022-03-14,Ethics Committee,CIP,"Version, dated and signed. In ES or EN"
ES,Spain,Pre-Market,1.0,2022-03-14,Ethics Committee,Synopsis,"Version, dated. In ES"
ES,Spain,Pre-Market,1.0,2022-03-14,Ethics Committee,CRF,
ES,Spain,Pre-Market,1.0,2022-03-14,Ethics Committee,IB,
ES,Spain,Pre-Market,1.0,2022-03-14,Ethics Committee,Recruitment plan,
ES,Spain,Pre-Market,1.0,2022-03-14,Ethics Committee,ICF & patient information,
ES,Spain,Pre-Market,1.0,2022-03-14,Ethics Committee,"Project Budget, compensation & other economic expenditure",
ES,Spain,Pre-Market,1.0,2022-03-14,Ethics Committee,Proof of insurance,
ES,Spain,Pre-Market,1.0,2022-03-14,Ethics Committee,Receipt of payment,
ES,Spain,Pre-Market,1.0,2022-03-14,Ethics Committee,"PI Cvs, GCPS.",
ES,Spain,Pre-Market,1.0,2022-03-14,Ethics Committee,PI commitment to the proyect,
ES,Spain,Post-Market,1.0,2022-03-14,Ethics Committee,Cover Letter ,"Evaluation of protocols, signed by sponsor/PI, indicating code & title of study. Indicate the pathway of EC evaluation (pre or post market), & the lists of participating centers. Writing the lists of documents that will be submitted"
ES,Spain,Post-Market,1.0,2022-03-14,Ethics Committee,CIP,"Version, dated and signed. In ES or EN"
ES,Spain,Post-Market,1.0,2022-03-14,Ethics Committee,Synopsis,"Version, dated. In ES"
ES,Spain,Post-Market,1.0,2022-03-14,Ethics Committee,CRF,
ES,Spain,Post-Market,1.0,2022-03-14,Ethics Committee,CE marking certification,
ES,Spain,Post-Market,1.0,2022-03-14,Ethics Committee,IB,
ES,Spain,Post-Market,1.0,2022-03-14,Ethics Committee,Recruitment plan,
ES,Spain,Post-Market,1.0,2022-03-14,Ethics Committee,ICF & patient information,
ES,Spain,Post-Market,1.0,2022-03-14,Ethics Committee,"Project Budget, compensation & other economic expenditure",
ES,Spain,Post-Market,1.0,2022-03-14,Ethics Committee,Proof of insurance,
ES,Spain,Post-Market,1.0,2022-03-14,Ethics Committee,Receipt of payment,
ES,Spain,Post-Market,1.0,2022-03-14,Ethics Committee,"PI Cvs, GCPS.",
ES,Spain,Post-Market,1.0,2022-03-14,Ethics Committee,PI commitment to the proyect,
FI,Finland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Post-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Post-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Post-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Post-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Post-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Post-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Post-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Post-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Post-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Post-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Post-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Post-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Post-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Post-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Post-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Post-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Post-Market,1.0,2022-03-14,Ethics Committee,,
FI,Finland,Post-Market,1.0,2022-03-14,Ethics Committee,,
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Main,
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Application form (FAEC) ,Please refer to Annex 2 of AAP-part 2
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Clinical evaluation plan (CEP),summary of the clinical evaluation plan (precise Version number and Date)
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Investigator brochure (IB),(precise version number and date)
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Clinical investigation plan (PROTOCOLE),Containing all items of annex XV chap II.3 (precise Version number and Date)
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Protocol synopsis (RESUME),French
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Other information (Please refer to Annex XV chap II 4),
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,"Signed statement by the natural or legal person responsible for the manufacture of the investigational device in question that it conforms to the general safety and performance requirements apart from the aspects covered by the clinical investigation and that, with regards to those aspects, every precaution has been taken to protect the health and safety of the subject",
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Signed statement that the sponsor is aware that the competent authority may contact the ethics committee that is assessing or has assessed the application,
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Proof of insurance (ASSURANCE) cover or indemnification of subjects in case of injury,"The proof of insurance cover must comply with the articles L. 1121-10 and 
R.1121-4 to R1121-9 of the French public health code. It must cover at least 
the period between the first inclusion and the last visit of a French participant. 
It must mention the estimated end date of the study and the contact details 
of the EU legal representative. IN FRENCH"
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Documents to be used to obtain informed consent (NIFC),"Please refer to page 7 of AAP-part 2 for details regarding the modalities of 
submission. IN FRENCH"
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,"Patient Information form (including all written information to participants, and compensation of participants)",In French
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Informed consent sheet,In French
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Informed consent process,In French
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,"All the document used to recruit participants (letter to general practitioners, posters, explanatory booklets, websites, etc.) (RECRUTEMENT)",In french
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Description of the arrangements to comply with the applicable rules on the protection and confidentiality of personal data/ personal information (refer to annex XV chap II 4.5) (DONNEES),Please refer to page 7 of AAP part 2 for details
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Copy of the opinion of the Ethics Committee (CPP) if available (to be submitted as soon as available) (AVIS),if applicable
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Technical file (DOSSIER_TECHNIQUE),
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Instruction for use for the clinical investigation ,Version No & Date
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,"Risk management, risk analysis",
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,List of standards and common specifications applied (if not included in the IB),(precise Version number and Date)
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,List of technical and functional features and the related expected clinical outcomes of the studied medical device,
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Critical analysis of non-clinical and clinical data related to the MD studied in relation to the evaluation of the benefits and risks of the investigation,
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Pre-clinical data,
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Clinical data,
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Other documents - National requirements (DOCUMENTS),
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,"Investigator list, proof of suitability of clinical investigators (LISTE_CV) and of suitability of investigational sites and investigational site team (EQUIPEMENT) ",Please refer to page 7 of AAP for details regarding the CV
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Authorisation of the investigational site (JUS_EQUIPEMENT),
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Import certificate for investigational medicinal products used in the IC ,If applicable. In French
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,Copy of the authorization issued by the third party to the sponsor to communicate the data related to the MD,
FR,France,Pre-Market,1.0,2022-03-14,Ethics Committee,PMCF plan,
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,Main,
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,Application form (FAEC) ,Please refer to Annex 2 of AAP-part 2
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,Clinical evaluation plan (CEP),summary of the clinical evaluation plan (precise Version number and Date)
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,Instruction for use (IFU) for CE medical device used within or without the scope of its intended purpose,(precise version number and date)
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,Clinical investigation plan (PROTOCOLE),Containing all items of annex XV chap II.3 (precise Version number and Date)
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,Protocol synopsis (RESUME),French
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,Other information (Please refer to Annex XV chap II 4),
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,Signed statement that the sponsor is aware that the competent authority may contact the ethics committee that is assessing or has assessed the application,
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,Proof of insurance (ASSURANCE) cover or indemnification of subjects in case of injury,"The proof of insurance cover must comply with the articles L. 1121-10 and 
R.1121-4 to R1121-9 of the French public health code. It must cover at least 
the period between the first inclusion and the last visit of a French participant. 
It must mention the estimated end date of the study and the contact details 
of the EU legal representative. IN FRENCH"
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,Documents to be used to obtain informed consent (NIFC),"Please refer to page 7 of AAP-part 2 for details regarding the modalities of 
submission. IN FRENCH"
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,"Patient Information form (including all written information to participants, and compensation of participants)",In French
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,Informed consent sheet,In French
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,Informed consent process,In French
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,"All the document used to recruit participants (letter to general practitioners, posters, explanatory booklets, websites, etc.) (RECRUTEMENT)",In french
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,Description of the arrangements to comply with the applicable rules on the protection and confidentiality of personal data/ personal information (refer to annex XV chap II 4.5) (DONNEES),Please refer to page 7 of AAP part 2 for details
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,Copy of the opinion of the Ethics Committee (CPP) if available (to be submitted as soon as available) (AVIS),if applicable
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,Technical file (DOSSIER_TECHNIQUE),
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,Statement of conformity: EC declaration of conformity or EU declaration of conformity ,(refer to art.19)
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,EC certificate,
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,Instructions for use for the clinical investigation ,(precise Version number and Date)
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,Other documents - National requirements (DOCUMENTS),
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,"Investigator list, proof of suitability of clinical investigators (LISTE_CV) and of suitability of investigational sites and investigational site team (EQUIPEMENT) ",Please refer to page 7 of AAP for details regarding the CV
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,Import certificate for investigational medicinal products used in the IC ,If applicable. In French
FR,France,Post-Market,1.0,2022-03-14,Ethics Committee,PMCF plan,
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,I. Cover letter which will include a list of contents,
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,"II. General Part: The documentation to be included in the General Part of the filing file to the EOF is set out in Annex XV, Chapter II of Regulation (EU) 2017/745.",
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,Application Form,
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,Investigator Brochure (IB),
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,Clinical Investigation Plan (CIP),
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,Compliance statement letter,
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,Insurance certificate,
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,Patient informed consent form (ICF),
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,Data confidentiality letter,
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,Instruction for use (IFU),
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,Case report form (CRF),
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,"III. Special Part: In addition to the supporting documents of the General Part, the file to the EOF will include the following Special supporting documents:",
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,"Completed the application form in Greek (available on the EOF website), in searchable pdf format, with signature, signatory details and date  ",
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,"General Summary of the clinical investigation plan (SYNOPSIS) in the Greek language (Relative to Section 3.1.5 of Reg. 2017/745, Par. XV, Chapter II)",
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,"Patient information and consent form (s), in Greek (& original in English if available). ",
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,Agreement PI & Sponsor,
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,"PI CVs, GCPs",
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,"If the applicant is not the sponsor, a letter of authorization to the applicant to act on behalf of the sponsor.",
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,CE marking certificate (if aplicable),
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,"Model of the label in the Greek language in which there will be, among other information, the labeling ""exclusively for clinical trials"".",
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,"Responsible statement from the sponsor stating whether the product contains as an integral part of the substance or derivative of human blood (in addition to Point 2.6 of Reg. 2017/745, Par. XV, Chapter II).",
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,Proof of payment of a fee in favor of EOF,
GK,Guernse,Pre-Market,1.0,2022-03-14,Ethics Committee,Study Budget,
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,I. Cover letter which will include a list of contents,
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,"II. General Part: The documentation to be included in the General Part of the filing file to the EOF is set out in Annex XV, Chapter II of Regulation (EU) 2017/745.",
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,Application Form,
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,Investigator Brochure (IB),
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,Clinical Investigation Plan (CIP),
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,Compliance statement letter,
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,Insurance certificate,
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,Patient informed consent form (ICF),
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,Data confidentiality letter,
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,Instruction for use (IFU),
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,Case report form (CRF),
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,"III. Special Part: In addition to the supporting documents of the General Part, the file to the EOF will include the following Special supporting documents:",
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,"Completed the application form in Greek (available on the EOF website), in searchable pdf format, with signature, signatory details and date  ",
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,"General Summary of the clinical investigation plan (SYNOPSIS) in the Greek language (Relative to Section 3.1.5 of Reg. 2017/745, Par. XV, Chapter II)",
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,"Patient information and consent form (s), in Greek (& original in English if available). ",
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,Agreement PI & Sponsor,
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,"PI CVs, GCPs",
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,"If the applicant is not the sponsor, a letter of authorization to the applicant to act on behalf of the sponsor.",
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,CE marking certificate (if aplicable),
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,"Model of the label in the Greek language in which there will be, among other information, the labeling ""exclusively for clinical trials"".",
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,"Responsible statement from the sponsor stating whether the product contains as an integral part of the substance or derivative of human blood (in addition to Point 2.6 of Reg. 2017/745, Par. XV, Chapter II).",
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,Proof of payment of a fee in favor of EOF,
GK,Guernse,Post-Market,1.0,2022-03-14,Ethics Committee,Study Budget,
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Ethics Committee,Cover Letter,
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Ethics Committee,Application Form ,
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Ethics Committee,CIP,
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Ethics Committee,Synopsis,
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Ethics Committee,Patient Consent Statement (ICF),
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Ethics Committee,The Declaration of Compliance with the Declaration of Helsinki ,Download from the website
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Ethics Committee,"CVs, GCPs of PI",
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Ethics Committee,"List of publications of the supervisor and participants in the research, if not included in the MTMT database. ","(Please indicate A letter of intent from the study director or coordinating study director, in which he or she undertakes to carry out the study Letter (s) of support from the head (s) of the institution - statement (s) of acceptance"
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Ethics Committee,Privacy/Confidentiality statement ,
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Ethics Committee,Institutional liability insurance in the case of an intervention investigation.,
HR,Croatia (local name: Hrvatska),Pre-Market,1.0,2022-03-14,Ethics Committee,Proof of payment of the service fee.,
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Ethics Committee,Cover Letter,
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Ethics Committee,Application Form ,
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Ethics Committee,CIP,
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Ethics Committee,Synopsis,
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Ethics Committee,Patient Consent Statement (ICF),
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Ethics Committee,The Declaration of Compliance with the Declaration of Helsinki ,Download from the website
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Ethics Committee,"CVs, GCPs of PI",
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Ethics Committee,"List of publications of the supervisor and participants in the research, if not included in the MTMT database. ","(Please indicate A letter of intent from the study director or coordinating study director, in which he or she undertakes to carry out the study Letter (s) of support from the head (s) of the institution - statement (s) of acceptance"
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Ethics Committee,Privacy/Confidentiality statement ,
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Ethics Committee,Institutional liability insurance in the case of an intervention investigation.,
HR,Croatia (local name: Hrvatska),Post-Market,1.0,2022-03-14,Ethics Committee,Proof of payment of the service fee.,
IE,Ireland,Pre-Market,1.0,2022-03-14,Ethics Committee,Cover Letter (On headed paper),
IE,Ireland,Pre-Market,1.0,2022-03-14,Ethics Committee,Aplication Form,Download from web
IE,Ireland,Pre-Market,1.0,2022-03-14,Ethics Committee,"All PI Cvs, GCPs",
IE,Ireland,Pre-Market,1.0,2022-03-14,Ethics Committee,Patient information leaflet,
IE,Ireland,Pre-Market,1.0,2022-03-14,Ethics Committee,PICF,
IE,Ireland,Pre-Market,1.0,2022-03-14,Ethics Committee,Proof of insurance/indemnity,
IE,Ireland,Pre-Market,1.0,2022-03-14,Ethics Committee,Site suitability form ,Download from web
IE,Ireland,Pre-Market,1.0,2022-03-14,Ethics Committee,Data Protection,
IE,Ireland,Pre-Market,1.0,2022-03-14,Ethics Committee,Details of any Data Monitoring Committee,
IE,Ireland,Pre-Market,1.0,2022-03-14,Ethics Committee,Signed Statement of Conformity to Safety and Performance Requirements ,
IE,Ireland,Pre-Market,1.0,2022-03-14,Ethics Committee,Letter of the Sponsor,
IE,Ireland,Pre-Market,1.0,2022-03-14,Ethics Committee,CRF,
IE,Ireland,Pre-Market,1.0,2022-03-14,Ethics Committee,Copies of Advertisement Material for Research Participants,
IE,Ireland,Pre-Market,1.0,2022-03-14,Ethics Committee,CIP,INCLUDING MANDATORY ITEMS stated in the checlist
IE,Ireland,Pre-Market,1.0,2022-03-14,Ethics Committee,IB,INCLUDING MANDATORY ITEMS stated in the checlist
IE,Ireland,Post-Market,1.0,2022-03-14,Ethics Committee,Cover Letter (On headed paper),
IE,Ireland,Post-Market,1.0,2022-03-14,Ethics Committee,Aplication Form,Download from web
IE,Ireland,Post-Market,1.0,2022-03-14,Ethics Committee,"All PI Cvs, GCPs",
IE,Ireland,Post-Market,1.0,2022-03-14,Ethics Committee,Patient information leaflet,
IE,Ireland,Post-Market,1.0,2022-03-14,Ethics Committee,PICF,
IE,Ireland,Post-Market,1.0,2022-03-14,Ethics Committee,Proof of insurance/indemnity,
IE,Ireland,Post-Market,1.0,2022-03-14,Ethics Committee,Site suitability form ,Download from web
IE,Ireland,Post-Market,1.0,2022-03-14,Ethics Committee,Data Protection,
IE,Ireland,Post-Market,1.0,2022-03-14,Ethics Committee,Details of any Data Monitoring Committee,
IE,Ireland,Post-Market,1.0,2022-03-14,Ethics Committee,Signed Statement of Conformity to Safety and Performance Requirements ,
IE,Ireland,Post-Market,1.0,2022-03-14,Ethics Committee,Letter of the Sponsor,
IE,Ireland,Post-Market,1.0,2022-03-14,Ethics Committee,CRF,
IE,Ireland,Post-Market,1.0,2022-03-14,Ethics Committee,Copies of Advertisement Material for Research Participants,
IE,Ireland,Post-Market,1.0,2022-03-14,Ethics Committee,CIP,INCLUDING MANDATORY ITEMS stated in the checlist
IE,Ireland,Post-Market,1.0,2022-03-14,Ethics Committee,IB,INCLUDING MANDATORY ITEMS stated in the checlist
IS,Iceland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Post-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Post-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Post-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Post-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Post-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Post-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Post-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Post-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Post-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Post-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Post-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Post-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Post-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Post-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Post-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Post-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Post-Market,1.0,2022-03-14,Ethics Committee,,
IS,Iceland,Post-Market,1.0,2022-03-14,Ethics Committee,,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,CONTACT REGIONAL EC FOR MORE DETAILS,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,"Letter from the sponsor requesting an opinion for the study (specify the title, duration and specific type of the study)",
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,"Letter of proxy from the Sponsor, if the CRO is present= Sponsor delegation of authority",
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Single and definitive opinion of the Coordinating Center Ethics Committee limited to observational studies of prospective and drug cohort,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Complete study protocol and any amendments with version and date on each page (CIP),
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Synopsis of the protocol in Italian (indicate version of the protocol),
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Patient Information Form with version and date on each page,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,ICF (indicate the version),
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Information and consent form for the processing of personal data (download from Webpage),
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Statement by the Coordinator on the observational nature of the study,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,"Details regarding the manager, the staff and the location where the study will take place",
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,List of participating centers dated and with protocol version,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee," ""Contract for conducting clinical trials on medicines"" Form (Download)",
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,List of information to be collected,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Declaration of cost coverage,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Identification of funding sources,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Investigator’s CVs dated and signed,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Investigator's application dated and signed,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,"If the study is sponsored, receipt of the transfer or declaration from the Promoter in the case of a non-profit study",
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,EC documents list,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,"Please submit the following application in this way: Send a hard copy and an electronic copy (cd-rom) of the documents listed below to the Secretariat Office of the Ethics Committee, Pav. 3 - New Entrance Careggi (NIC) - Didactics - Largo Brambilla, 3 - 50134 Florence",Region Toscana: https://www.aou-careggi.toscana.it/internet/index.php?option=com_content&view=article&id=4385&Itemid=962&lang=it
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Documents ,Note
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Letter of Intent (Form in webpage),
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Synopsis in Italian (Form in webpage),
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Complete study protocol and any amendments with version and date on each page (CIP),
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,List of participating sites,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Data collection information (CRF),
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Insurance certificate in Italian (if applicable),
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Receipt of the payment of the amount established by the Tuscany Region for the examination of the study protocol,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Economic agreement (Form on webpage),
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Informed Consent Form in Italian (Form on webpage),
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Device user manual = IFU?,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,CE Marking Certification ,
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Device Preliminary CheckList (Form in webpage),CHECK if the device has registered in Italy. https://www.salute.gov.it/interrogazioneDispositivi/RicercaDispositiviServlet?action=ACTION_MASCHERA 
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,PI Acceptance Form (on webpage),
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,"PI CVs, GCPs.. Up to date",
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Feasibility Assessment (Form on webpage),
IT,Italy,Pre-Market,1.0,2022-03-14,Ethics Committee,Public Statement on Local Investigator's Conflict of Interest (Form on webpage),
IT,Italy,Post-Market,1.0,2022-03-14,Ethics Committee,CONTACT REGIONAL EC FOR MORE DETAILS. ,
IT,Italy,Post-Market,1.0,2022-03-14,Ethics Committee,"Letter from the sponsor requesting an opinion for the study (specify the title, duration and specific type of the study)",
IT,Italy,Post-Market,1.0,2022-03-14,Ethics Committee,"Letter of proxy from the Sponsor, if the CRO is present= Sponsor delegation of authority",
IT,Italy,Post-Market,1.0,2022-03-14,Ethics Committee,Single and definitive opinion of the Coordinating Center Ethics Committee limited to observational studies of prospective and drug cohort,
IT,Italy,Post-Market,1.0,2022-03-14,Ethics Committee,Complete study protocol and any amendments with version and date on each page (CIP),
IT,Italy,Post-Market,1.0,2022-03-14,Ethics Committee,Synopsis of the protocol in Italian (indicate version of the protocol),
IT,Italy,Post-Market,1.0,2022-03-14,Ethics Committee,Patient Information Form with version and date on each page,
IT,Italy,Post-Market,1.0,2022-03-14,Ethics Committee,ICF (indicate the version),
IT,Italy,Post-Market,1.0,2022-03-14,Ethics Committee,Information and consent form for the processing of personal data (download from Webpage),
IT,Italy,Post-Market,1.0,2022-03-14,Ethics Committee,Statement by the Coordinator on the observational nature of the study,
IT,Italy,Post-Market,1.0,2022-03-14,Ethics Committee,"Details regarding the manager, the staff and the location where the study will take place",
IT,Italy,Post-Market,1.0,2022-03-14,Ethics Committee,List of participating centers dated and with protocol version,
IT,Italy,Post-Market,1.0,2022-03-14,Ethics Committee," ""Contract for conducting clinical trials on medicines"" Form (Download)",
IT,Italy,Post-Market,1.0,2022-03-14,Ethics Committee,List of information to be collected,
IT,Italy,Post-Market,1.0,2022-03-14,Ethics Committee,Declaration of cost coverage,
IT,Italy,Post-Market,1.0,2022-03-14,Ethics Committee,Identification of funding sources,
IT,Italy,Post-Market,1.0,2022-03-14,Ethics Committee,Investigator’s CVs dated and signed,
IT,Italy,Post-Market,1.0,2022-03-14,Ethics Committee,Investigator's application dated and signed,
IT,Italy,Post-Market,1.0,2022-03-14,Ethics Committee,"If the study is sponsored, receipt of the transfer or declaration from the Promoter in the case of a non-profit study",
LT,Lithuania,Pre-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Pre-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Post-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Post-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Post-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Post-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Post-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Post-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Post-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Post-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Post-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Post-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Post-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Post-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Post-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Post-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Post-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Post-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Post-Market,1.0,2022-03-14,Ethics Committee,,
LT,Lithuania,Post-Market,1.0,2022-03-14,Ethics Committee,,
LV,Latvia,Pre-Market,1.0,2022-03-14,Ethics Committee,Protocols,
LV,Latvia,Pre-Market,1.0,2022-03-14,Ethics Committee,Synopsis,
LV,Latvia,Pre-Market,1.0,2022-03-14,Ethics Committee,the description of measures for involvement of the trial subjects,Recruitment plan
LV,Latvia,Pre-Market,1.0,2022-03-14,Ethics Committee,Aplication Form,Paragraph 63 Regulation No. 891 
LV,Latvia,Pre-Market,1.0,2022-03-14,Ethics Committee,the documentation specifying whether compensation related to the participation in the trial is anticipated for the trial subject,
LV,Latvia,Pre-Market,1.0,2022-03-14,Ethics Committee,Patient Information and ICF,
LV,Latvia,Pre-Market,1.0,2022-03-14,Ethics Committee,Proof of payment,
LV,Latvia,Pre-Market,1.0,2022-03-14,Ethics Committee,a power of attorney issued by the manufacturer if the documents are submitted by his or her authorized representative (the manufacturer shall ensure that his or her authorized representative is registered in a Member State of the European Union or a country of the European Economic Area),
LV,Latvia,Pre-Market,1.0,2022-03-14,Ethics Committee,Proof of insurance,
LV,Latvia,Pre-Market,1.0,2022-03-14,Ethics Committee,"PI CVs, GCPs",
LV,Latvia,Pre-Market,1.0,2022-03-14,Ethics Committee,Risk analysis,
LV,Latvia,Pre-Market,1.0,2022-03-14,Ethics Committee,NOTE,"Meetings of the Ethics Committee take place on the 1st Thursday of the month, applications must be submitted no later than 5 working days in advance."
LV,Latvia,Post-Market,1.0,2022-03-14,Ethics Committee,Protocols,
LV,Latvia,Post-Market,1.0,2022-03-14,Ethics Committee,Synopsis,
LV,Latvia,Post-Market,1.0,2022-03-14,Ethics Committee,the description of measures for involvement of the trial subjects,Recruitment plan
LV,Latvia,Post-Market,1.0,2022-03-14,Ethics Committee,Aplication Form,Paragraph 63 Regulation No. 891 
LV,Latvia,Post-Market,1.0,2022-03-14,Ethics Committee,the documentation specifying whether compensation related to the participation in the trial is anticipated for the trial subject,
LV,Latvia,Post-Market,1.0,2022-03-14,Ethics Committee,Patient Information and ICF,
LV,Latvia,Post-Market,1.0,2022-03-14,Ethics Committee,Proof of payment,
LV,Latvia,Post-Market,1.0,2022-03-14,Ethics Committee,a power of attorney issued by the manufacturer if the documents are submitted by his or her authorized representative (the manufacturer shall ensure that his or her authorized representative is registered in a Member State of the European Union or a country of the European Economic Area),
LV,Latvia,Post-Market,1.0,2022-03-14,Ethics Committee,Proof of insurance,
LV,Latvia,Post-Market,1.0,2022-03-14,Ethics Committee,"PI CVs, GCPs",
LV,Latvia,Post-Market,1.0,2022-03-14,Ethics Committee,Risk analysis,
LV,Latvia,Post-Market,1.0,2022-03-14,Ethics Committee,NOTE,"Meetings of the Ethics Committee take place on the 1st Thursday of the month, applications must be submitted no later than 5 working days in advance."
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Ethics Committee,Cover Letter ( Requesting authorisation for the study),File name: Protocol number_courrierAEC_date(ddmmyy)_version
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Ethics Committee,Aplication form ,
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Ethics Committee,EU test number & Universal test number ,
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Ethics Committee,Protocol ,File name: Protocol number_protocol_date(ddmmyy)_version
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Ethics Committee,Protocol summary/ Synopsis,File name: Protocol number_summary_date(ddmmyy)_version
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Ethics Committee,IB,File name: Protocol number_BI_date(ddmmyy)_version
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Ethics Committee,Dossier of the investigational product,
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Ethics Committee,"CE Certificate, if aplicable",
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Ethics Committee,Manufacturing and import authorization,
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Ethics Committee,Labeling of investigational product,
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Ethics Committee,"Scientific advice and pediatric investigation plan (PIP), if applicable",
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Ethics Committee,Technical File,File name: Protocol number_DT_date(ddmmyy)_version
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Ethics Committee,"CRF, evaluation grids, questionnaire",
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Ethics Committee,"PI Cvs, GCPs",
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Ethics Committee,ICF & patient information,French & German 
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Ethics Committee,Proof of insurance or compensation,
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Ethics Committee,Justification of the adequacy of the infrastructures,
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Ethics Committee,Study funding,
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Ethics Committee,Proof of payment fee,
LU,Luxembourg,Pre-Market,1.0,2022-03-14,Ethics Committee,NOTE,The Luxembourg Ministry of Health is the only point of submission of files. The Ministry of Health is responsible for sending the study files to the Health Department and the National Research Ethics Committee.
LU,Luxembourg,Post-Market,1.0,2022-03-14,Ethics Committee,Cover Letter ( Requesting authorisation for the study),File name: Protocol number_courrierAEC_date(ddmmyy)_version
LU,Luxembourg,Post-Market,1.0,2022-03-14,Ethics Committee,Aplication form ,
LU,Luxembourg,Post-Market,1.0,2022-03-14,Ethics Committee,EU test number & Universal test number ,
LU,Luxembourg,Post-Market,1.0,2022-03-14,Ethics Committee,Protocol ,File name: Protocol number_protocol_date(ddmmyy)_version
LU,Luxembourg,Post-Market,1.0,2022-03-14,Ethics Committee,Protocol summary/ Synopsis,File name: Protocol number_summary_date(ddmmyy)_version
LU,Luxembourg,Post-Market,1.0,2022-03-14,Ethics Committee,IB,File name: Protocol number_BI_date(ddmmyy)_version
LU,Luxembourg,Post-Market,1.0,2022-03-14,Ethics Committee,Dossier of the investigational product,
LU,Luxembourg,Post-Market,1.0,2022-03-14,Ethics Committee,"CE Certificate, if aplicable",
LU,Luxembourg,Post-Market,1.0,2022-03-14,Ethics Committee,Manufacturing and import authorization,
LU,Luxembourg,Post-Market,1.0,2022-03-14,Ethics Committee,Labeling of investigational product,
LU,Luxembourg,Post-Market,1.0,2022-03-14,Ethics Committee,"Scientific advice and pediatric investigation plan (PIP), if applicable",
LU,Luxembourg,Post-Market,1.0,2022-03-14,Ethics Committee,Technical File,File name: Protocol number_DT_date(ddmmyy)_version
LU,Luxembourg,Post-Market,1.0,2022-03-14,Ethics Committee,"CRF, evaluation grids, questionnaire",
LU,Luxembourg,Post-Market,1.0,2022-03-14,Ethics Committee,"PI Cvs, GCPs",
LU,Luxembourg,Post-Market,1.0,2022-03-14,Ethics Committee,ICF & patient information,French & German 
LU,Luxembourg,Post-Market,1.0,2022-03-14,Ethics Committee,Proof of insurance or compensation,
LU,Luxembourg,Post-Market,1.0,2022-03-14,Ethics Committee,Justification of the adequacy of the infrastructures,
LU,Luxembourg,Post-Market,1.0,2022-03-14,Ethics Committee,Study funding,
LU,Luxembourg,Post-Market,1.0,2022-03-14,Ethics Committee,Proof of payment fee,
LU,Luxembourg,Post-Market,1.0,2022-03-14,Ethics Committee,NOTE,The Luxembourg Ministry of Health is the only point of submission of files. The Ministry of Health is responsible for sending the study files to the Health Department and the National Research Ethics Committee.
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Pre-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Ethics Committee,,
MD,Republic of Moldov,Post-Market,1.0,2022-03-14,Ethics Committee,,
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,A1. Cover Letter,Download template
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,A2. Authorization form the sponsor OR Authorisation from legal representative EU if sponsor does not hold offices within EU,
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,B1. Application Form,complete the ABR form in ToetsingOnline. https://english.ccmo.nl/investigators/clinical-investigations-with-medical-devices/standard-research-file-medical-devices/b-forms/b1-abr-form
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,B2. Eudamed registration,
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,C1. Protocols (CIP),
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,C2. CIP amendments,if aplicable
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,D1. IB ,
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,D2. Investiogational MD Dossier (IMDD),
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,D3. Manufacturer statement on safety and performances,
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,E1/E2a. Template Subject Information Sheet for research subjects <16 years of age (children) (if aplicable to the study),"The templates are updated regularly. At all times, use the most recent versions of the templates as available on this website."
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,E1/E2b. Template Subject Information Sheet for research subjects > 16 years of age (adults),
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,E3. Promotional materials research subjects,If aplicable
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,E4. Other informational materials,If aplicable
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,E5. Newsletters or letters with study results,If aplicable
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,F1. Questionnaire. F2 Patient Diaries. F3. Patient cards. F4. Other ,If aplicable
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,G1. Proof of insurance,
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,G2. Proof of coverage,
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,"H2. PI Cv, GCP",
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,I1. List of participating centers,
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,I2. Site sustainability,
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,"I3. Centers PI CVs, GCPs",
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,J1. Financial compensation for research subjects,This is only applicable when the information in the ABR form is not sufficient.
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,J2. Financial compensation for investigators and participating centres,This is only applicable when the information in the ABR form is not sufficient.
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,K1. Recommendations other authorities,If aplicable
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,K2. Assessment other EU member states,If aplicable
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,K3. Clinical trial agreements,If aplicable
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,K4. Scientific publications,If aplicable
NL,Netherlands,Pre-Market,1.0,2022-03-14,Ethics Committee,K5. Data Safety Monitoring Board (DSMB),If aplicable
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,A1. Cover Letter,Download template
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,A2. Authorization form the sponsor OR Authorisation from legal representative EU if sponsor does not hold offices within EU,
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,B1. Application Form,complete the ABR form in ToetsingOnline. https://english.ccmo.nl/investigators/clinical-investigations-with-medical-devices/standard-research-file-medical-devices/b-forms/b1-abr-form
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,B2. Eudamed registration,
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,C1. Protocols (CIP),
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,C2. CIP amendments,if aplicable
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,D1. IB or D2. IFU,Just one option
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,D3. Manufacturer statement on safety and performances,
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,E1/E2a. Template Subject Information Sheet for research subjects <16 years of age (children) (if aplicable to the study),"The templates are updated regularly. At all times, use the most recent versions of the templates as available on this website."
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,E1/E2b. Template Subject Information Sheet for research subjects > 16 years of age (adults),
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,E3. Promotional materials research subjects,If aplicable
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,E4. Other informational materials,If aplicable
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,E5. Newsletters or letters with study results,If aplicable
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,F1. Questionnaire. F2 Patient Diaries. F3. Patient cards. F4. Other ,If aplicable
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,G1. Proof of insurance,
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,G2. Proof of coverage,
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,"H2. PI Cv, GCP",
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,I1. List of participating centers,
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,I2. Site sustainability,
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,"I3. Centers PI CVs, GCPs",
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,J1. Financial compensation for research subjects,This is only applicable when the information in the ABR form is not sufficient.
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,J2. Financial compensation for investigators and participating centres,This is only applicable when the information in the ABR form is not sufficient.
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,K1. Recommendations other authorities,If aplicable
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,K2. Assessment other EU member states,If aplicable
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,K3. Clinical trial agreements,If aplicable
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,K4. Scientific publications,If aplicable
NL,Netherlands,Post-Market,1.0,2022-03-14,Ethics Committee,K5. Data Safety Monitoring Board (DSMB),If aplicable
NO,Norway,Pre-Market,1.0,2022-03-14,Ethics Committee,"PI CVs, GCPs",
NO,Norway,Pre-Market,1.0,2022-03-14,Ethics Committee,Research protocol,
NO,Norway,Pre-Market,1.0,2022-03-14,Ethics Committee,IB,
NO,Norway,Pre-Market,1.0,2022-03-14,Ethics Committee,EudraCT form,
NO,Norway,Pre-Market,1.0,2022-03-14,Ethics Committee,Questionnaire,
NO,Norway,Pre-Market,1.0,2022-03-14,Ethics Committee,Interview guide,
NO,Norway,Pre-Market,1.0,2022-03-14,Ethics Committee,Information sheet for children,If aplicable
NO,Norway,Pre-Market,1.0,2022-03-14,Ethics Committee,Request for participation and consent declaration for parents where research is conducted on minors,If aplicable
NO,Norway,Pre-Market,1.0,2022-03-14,Ethics Committee,Request for participation and consent declaration for adults,
NO,Norway,Pre-Market,1.0,2022-03-14,Ethics Committee,IFU,
NO,Norway,Pre-Market,1.0,2022-03-14,Ethics Committee,CIP,
NO,Norway,Pre-Market,1.0,2022-03-14,Ethics Committee,Synopsis,
NO,Norway,Pre-Market,1.0,2022-03-14,Ethics Committee,Data protection,
NO,Norway,Pre-Market,1.0,2022-03-14,Ethics Committee,Risk analysis,
NO,Norway,Pre-Market,1.0,2022-03-14,Ethics Committee,Proof of insurance,
NO,Norway,Pre-Market,1.0,2022-03-14,Ethics Committee,NOTE,"As a rule, applications must be written in Norwegian. If the project is to be carried out in its entirety abroad, the application can be made in English. Files uploaded must be in PDF format (Adobe acrobat)"
NO,Norway,Post-Market,1.0,2022-03-14,Ethics Committee,"PI CVs, GCPs",
NO,Norway,Post-Market,1.0,2022-03-14,Ethics Committee,Research protocol,
NO,Norway,Post-Market,1.0,2022-03-14,Ethics Committee,IB,
NO,Norway,Post-Market,1.0,2022-03-14,Ethics Committee,EudraCT form,
NO,Norway,Post-Market,1.0,2022-03-14,Ethics Committee,Questionnaire,
NO,Norway,Post-Market,1.0,2022-03-14,Ethics Committee,Interview guide,
NO,Norway,Post-Market,1.0,2022-03-14,Ethics Committee,Information sheet for children,If aplicable
NO,Norway,Post-Market,1.0,2022-03-14,Ethics Committee,Request for participation and consent declaration for parents where research is conducted on minors,If aplicable
NO,Norway,Post-Market,1.0,2022-03-14,Ethics Committee,Request for participation and consent declaration for adults,
NO,Norway,Post-Market,1.0,2022-03-14,Ethics Committee,CE certificate,
NO,Norway,Post-Market,1.0,2022-03-14,Ethics Committee,IFU,
NO,Norway,Post-Market,1.0,2022-03-14,Ethics Committee,CIP,
NO,Norway,Post-Market,1.0,2022-03-14,Ethics Committee,Synopsis,
NO,Norway,Post-Market,1.0,2022-03-14,Ethics Committee,Data protection,
NO,Norway,Post-Market,1.0,2022-03-14,Ethics Committee,Risk analysis,
NO,Norway,Post-Market,1.0,2022-03-14,Ethics Committee,Proof of insurance,
NO,Norway,Post-Market,1.0,2022-03-14,Ethics Committee,NOTE,"As a rule, applications must be written in Norwegian. If the project is to be carried out in its entirety abroad, the application can be made in English. Files uploaded must be in PDF format (Adobe acrobat)"
PL,Poland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Pre-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Post-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Post-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Post-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Post-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Post-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Post-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Post-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Post-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Post-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Post-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Post-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Post-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Post-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Post-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Post-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Post-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Post-Market,1.0,2022-03-14,Ethics Committee,,
PL,Poland,Post-Market,1.0,2022-03-14,Ethics Committee,,
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,1.1.1 - Request,Annex I. https://www.ceic.pt/formularios
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,1.1.2 - Letter of Representation signed by the promoter (manufacturer or other),
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,"1.1.3 - List of Competent Authorities of the Member States involved, to which the request was submitted.",
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,1.1.4 - Opinions of the Ethics Commissions of the Member States involved.,
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,1.1.5 - Declaration of conformity,
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,1.1.6 - Form for notification related to medical devices intended for clinical investigation,
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,1.1.7- Proof of payment ,
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,"1.2.1.1.1 - CIF (Informed Consent Form and
Information Leaflet)",
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,1.2.1.1.2 - Patient card,
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,1.2.1.1.3 – Information about the contact person,
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,"Recruiment Mode, Publicity Material, Questionnaires",1.2.1.2; 1.2.1.3; 1.2.1.4 respectively
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,1.2.2.1 - Declaration of the conditions of the center for carrying out the study,Site sustainability
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,1.2.2.2 - Declaration of the DM circuit,
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,1.2.3.1.1 – CV of the Coordinating Investigator,
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,1.2.3.1.2 – CV of Principal Investigators,
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,1.2.4.1 - Insurance and Indemnities,
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,1.2.4.2 - Compensation/payments to Participants,
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,1.2.4.3 - Contracts,
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,1.2.4.3.1 - Study centers,
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,2.1. – Clinical investigation plan + amandments,
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,2.2 - Synopsis ,in Portuguese
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,2.3.1 - Clinical Trials with the same DM(s),optional
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,2.3.2 - Scientific Assessment,if aplicable
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,2.3.3 - Ethical Assessment,if aplicable
PT,Portugal,Pre-Market,1.0,2022-03-14,Ethics Committee,3.1 – Investigator’s Brochure,In case of pre-market
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,1.1.1 - Request,Annex I. https://www.ceic.pt/formularios
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,1.1.2 - Letter of Representation signed by the promoter (manufacturer or other),
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,"1.1.3 - List of Competent Authorities of the Member States involved, to which the request was submitted.",
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,1.1.4 - Opinions of the Ethics Commissions of the Member States involved.,
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,1.1.5 - Declaration of conformity,
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,CE certificate,PMCF
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,Labeling,PMCF
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,IFU ,PMCF
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,1.1.6 - Form for notification related to medical devices intended for clinical investigation,
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,1.1.7- Proof of payment ,
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,"1.2.1.1.1 - CIF (Informed Consent Form and
Information Leaflet)",
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,1.2.1.1.2 - Patient card,
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,1.2.1.1.3 – Information about the contact person,
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,"Recruiment Mode, Publicity Material, Questionnaires",1.2.1.2; 1.2.1.3; 1.2.1.4 respectively
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,1.2.2.1 - Declaration of the conditions of the center for carrying out the study,Site sustainability
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,1.2.2.2 - Declaration of the DM circuit,
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,1.2.3.1.1 – CV of the Coordinating Investigator,
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,1.2.3.1.2 – CV of Principal Investigators,
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,1.2.4.1 - Insurance and Indemnities,
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,1.2.4.2 - Compensation/payments to Participants,
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,1.2.4.3 - Contracts,
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,1.2.4.3.1 - Study centers,
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,2.1. – Clinical investigation plan + amandments,
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,2.2 - Synopsis ,in Portuguese
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,2.3.1 - Clinical Trials with the same DM(s),optional
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,2.3.2 - Scientific Assessment,if aplicable
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,2.3.3 - Ethical Assessment,if aplicable
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,3.1 – Investigator’s Brochure,In case of pre-market
PT,Portugal,Post-Market,1.0,2022-03-14,Ethics Committee,3.2- IFU ,In case of PMCF 
RO,Romania,Pre-Market,1.0,2022-03-14,Ethics Committee,Clinical trial protocol,
RO,Romania,Pre-Market,1.0,2022-03-14,Ethics Committee,IB,
RO,Romania,Pre-Market,1.0,2022-03-14,Ethics Committee,Synopsis ,In Serbian
RO,Romania,Pre-Market,1.0,2022-03-14,Ethics Committee,Proof of insurance,
RO,Romania,Pre-Market,1.0,2022-03-14,Ethics Committee,Procedures and documentation for obtaining ICF,In Serbian
RO,Romania,Pre-Market,1.0,2022-03-14,Ethics Committee,Procedures for the protection of vulnerable groups and individuals,
RO,Romania,Pre-Market,1.0,2022-03-14,Ethics Committee,Justification of the clinical trial from the ethical and scientific aspect,
RO,Romania,Pre-Market,1.0,2022-03-14,Ethics Committee,Appropriate benefit-risk assessment,
RO,Romania,Pre-Market,1.0,2022-03-14,Ethics Committee,"PI Cvs, GCPs",
RO,Romania,Pre-Market,1.0,2022-03-14,Ethics Committee,Site sustainability,
RO,Romania,Pre-Market,1.0,2022-03-14,Ethics Committee,Proof of fee payment,
RO,Romania,Pre-Market,1.0,2022-03-14,Ethics Committee,"Documentation (statement) regarding the conflict of interest of researchers in accordance with the law,",
RO,Romania,Pre-Market,1.0,2022-03-14,Ethics Committee,Documentation regarding the reimbursement of necessary costs,
RO,Romania,Pre-Market,1.0,2022-03-14,Ethics Committee,"Procedure regarding recruitment of respondents, including advertising, ie material with advertising elements",
RO,Romania,Post-Market,1.0,2022-03-14,Ethics Committee,Clinical trial protocol,
RO,Romania,Post-Market,1.0,2022-03-14,Ethics Committee,IB,
RO,Romania,Post-Market,1.0,2022-03-14,Ethics Committee,Synopsis ,In Serbian
RO,Romania,Post-Market,1.0,2022-03-14,Ethics Committee,Proof of insurance,
RO,Romania,Post-Market,1.0,2022-03-14,Ethics Committee,Procedures and documentation for obtaining ICF,In Serbian
RO,Romania,Post-Market,1.0,2022-03-14,Ethics Committee,Procedures for the protection of vulnerable groups and individuals,
RO,Romania,Post-Market,1.0,2022-03-14,Ethics Committee,Justification of the clinical trial from the ethical and scientific aspect,
RO,Romania,Post-Market,1.0,2022-03-14,Ethics Committee,Appropriate benefit-risk assessment,
RO,Romania,Post-Market,1.0,2022-03-14,Ethics Committee,"PI Cvs, GCPs",
RO,Romania,Post-Market,1.0,2022-03-14,Ethics Committee,Site sustainability,
RO,Romania,Post-Market,1.0,2022-03-14,Ethics Committee,Proof of fee payment,
RO,Romania,Post-Market,1.0,2022-03-14,Ethics Committee,"Documentation (statement) regarding the conflict of interest of researchers in accordance with the law,",
RO,Romania,Post-Market,1.0,2022-03-14,Ethics Committee,Documentation regarding the reimbursement of necessary costs,
RO,Romania,Post-Market,1.0,2022-03-14,Ethics Committee,"Procedure regarding recruitment of respondents, including advertising, ie material with advertising elements",
RS,Unknown,Pre-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Pre-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Pre-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Pre-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Pre-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Pre-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Pre-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Pre-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Pre-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Pre-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Pre-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Pre-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Pre-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Pre-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Pre-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Pre-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Pre-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Pre-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Post-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Post-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Post-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Post-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Post-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Post-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Post-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Post-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Post-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Post-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Post-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Post-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Post-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Post-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Post-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Post-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Post-Market,1.0,2022-03-14,Ethics Committee,,
RS,Unknown,Post-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Pre-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Ethics Committee,,
SI,Slovenia,Post-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Pre-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Ethics Committee,,
SK,Slovakia (Slovak republic),Post-Market,1.0,2022-03-14,Ethics Committee,,
SE,Sweden,Post-Market,1.0,2022-03-14,Ethics Committee,Instruction ,"For the ethical review, the first step is to fill in form 01 Description of the research project - medical devices. The form must be in Swedish and sent in as a searchable PDF. Then send all the documents to CA only. "
SE,Sweden,Pre-Market,1.0,2022-03-14,Ethics Committee,Instruction ,"For the ethical review, the first step is to fill in form 01 Description of the research project - medical devices. The form must be in Swedish and sent in as a searchable PDF. Then send all the documents to CA only. "
UA,Ukraine,Pre-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Pre-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Ethics Committee,,
UA,Ukraine,Post-Market,1.0,2022-03-14,Ethics Committee,,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Ethics Committee,Protocol,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Ethics Committee,Participant information sheet & ICF,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Ethics Committee,Data protection,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Ethics Committee,Organisation Information Document,Non-comercial & comercial version. For non-commercial studies it should be accompanied by a completed Schedule of Events.
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Ethics Committee,The Industry Costing Templates ,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Ethics Committee,Model Agreement,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Ethics Committee,Funding ,
UK,United Kingdo,Pre-Market,1.0,2022-03-14,Ethics Committee,"PI CVs, GCPs",
UK,United Kingdo,Post-Market,1.0,2022-03-14,Ethics Committee,Protocol,
UK,United Kingdo,Post-Market,1.0,2022-03-14,Ethics Committee,Participant information sheet & ICF,
UK,United Kingdo,Post-Market,1.0,2022-03-14,Ethics Committee,Data protection,
UK,United Kingdo,Post-Market,1.0,2022-03-14,Ethics Committee,Organisation Information Document,Non-comercial & comercial version. For non-commercial studies it should be accompanied by a completed Schedule of Events.
UK,United Kingdo,Post-Market,1.0,2022-03-14,Ethics Committee,The Industry Costing Templates ,
UK,United Kingdo,Post-Market,1.0,2022-03-14,Ethics Committee,Model Agreement,
UK,United Kingdo,Post-Market,1.0,2022-03-14,Ethics Committee,Funding ,
UK,United Kingdo,Post-Market,1.0,2022-03-14,Ethics Committee,"PI CVs, GCPs",
